Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Rheumatology | Musculoskeletal

Clinical Trials: Rheumatoid Arthritis


A listing of clinical trials currently looking for volunteers to enroll in Rheumatoid Arthritis studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Anniston : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Anniston : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Anniston : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Anniston : Investigational Site Number 840070 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Birmingham : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

View More »

Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Birmingham : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Huntsville : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Huntsville : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Huntsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Huntsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Huntsville : Site Reference ID/Investigator# 38982

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Huntsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Huntsville : 170

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Huntsville : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Huntsville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Huntsville : Rheumatology Associates Of North Alabama, P.C.

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Mobile : Mobile Diagnostic Center Rheumatology

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Mobile : 180

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Tuscaloosa :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Tuscaloosa : Site Reference ID/Investigator# 38686

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Tuscaloosa : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Arizona

Paradise Valley : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Paradise Valley : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Scottsdale : Radiant Research - Scottsdale

Rheumatoid Arthritis (RA) Research Study

View More »

Gilbert :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Gilbert : Investigational Site Number 840072 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Glendale : 247

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Glendale : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Glendale : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Glendale : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mesa : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Mesa : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Mesa : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Mesa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mesa : 166 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Paradise Valley : Site Reference ID/Investigator# 37983

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Paradise Valley : Site Reference ID/Investigator# 42044

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Paradise Valley : 234

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Paradise Valley : 165

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Paradise Valley : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Paradise Valley : 154 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Peoria : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Peoria : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Peoria : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Peoria : Sun Valley Arthritis Center, Ltd

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Phoenix : 243

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Phoenix : 187

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Phoenix : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Phoenix : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Phoenix : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Phoenix : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Scottsdale : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Scottsdale : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Scottsdale : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Scottsdale : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Scottsdale : 118 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tucson :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Tucson :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tucson : Tucson Orthopaedic Research Center

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Tucson : University of Arizona

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Tucson : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tucson : 159

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Arkansas

Hot Springs : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Jonesboro : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Jonesboro : NEA Baptist Clinic - Clinical Research Center

If you have RA and have had an inadequate response to a TNF-a inhibitor, contact us today!

View More »

Hot Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Hot Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Hot Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hot Springs : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hot Springs : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hot Springs : 103 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Hot Springs : 152

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Jonesboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Jonesboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Little Rock : Site Reference ID/Investigator# 44823

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Little Rock : 156

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Little Rock : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

California

La Jolla : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Los Angeles : University of California, Los Angeles Updated

A research study examining the effects of milnacipran for the treatment of pain in older adults with rheumatoid arthritis

Los Angeles : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

P Hemet : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Palo Alto : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Sacramento : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

San Diego : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

San Luis Obispo : Coastal Medical Research Group, Inc.

Have you been diagnosed with Oseoarthritis or Rheumatoid Arthritis?

Santa Maria : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Wildomar : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Covina : 160

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Covina : 127 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Covina : 147

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Encino : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Hemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Hemet : Site Reference ID/Investigator# 37981

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Hemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hemet : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Huntington Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Huntington Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Huntington Beach : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Huntington Beach : 164

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Huntington Beach : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Huntington Beach : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Inglewood : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

La Jolla : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

La Jolla : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

La Jolla : 148 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : Scripps Clinic

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

La Mesa :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lakewood :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Loma Linda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Loma Linda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Loma Linda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Long Beach : Site Reference ID/Investigator# 40208

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Long Beach : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Long Beach : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Long Beach : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Long Beach : 184 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Los Alamitos : Trial Concierge/Pacific Clinical Studies

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Los Angeles : Axis Clinical Trials

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Los Angeles : 159

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Los Angeles : UCLA Semel Institute

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

Los Angeles : 149

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Menifee : 144

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Murrieta : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Palm Desert :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Palm Desert : Desert Medical Advances

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Palo Alto : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Palo Alto : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Palo Alto : 104 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Sacramento : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Sacramento : Site Reference ID/Investigator# 38423

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Sacramento : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

San Diego :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

San Diego : San Diego Arthritis Medical Clinic

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

San Francisco : California Pacific Medical Center

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

San Francisco : Investigational Site Number 840008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

San Francisco : University of California, San Francisco

Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty

San Francisco : University of California, San Francisco Updated

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

San Leandro : 201

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Leandro : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Santa Maria :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Santa Maria : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Santa Maria : Investigational Site Number 840021 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santa Maria : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Santa Maria : 129 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Santa Monica : Orrin M. Troum, MD and Medical Associates

Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects

Santa Monica : Orrin M. Troum, MD and Medical Associates

Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Torrance : Novatis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Torrance : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Torrance : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tustin : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tustin : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Upland :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Upland : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Upland : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Upland : 202

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Upland : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Upland : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Upland : Investigational Site Number 840049 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Upland : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Upland : 164 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Victorville : Site Reference ID/Investigator# 38204

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Victorville : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Walnut Creek : Site Reference ID/Investigator# 40762

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Whittier :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Whittier : 172

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Colorado

Boulder : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

View More »

Colorado Springs : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Colorado Springs : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Colorado Springs : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Denver :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Denver : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Fort Collins : Orthopedic Center of the Rockies

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Connecticut

Bridgeport : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Stamford : Stamford Therapeutics Consortium

Rheumatoid Arthritis pain?

Trumbull : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Bridgeport :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Bridgeport : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Bridgeport : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Danbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Danbury : Site Reference ID/Investigator# 43049

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Danbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Danbury : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hamden : 141 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Trumbull : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Trumbull : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Trumbull : New England Research Associates, Llc

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Delaware

Lewes : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lewes : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Lewes : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lewes : 111 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Newark : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Florida

Aventura : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Aventura : South Florida Medical Research

Phase IV, Double-Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen.

Aventura : South Florida Medical Research

Study of patients with Osteoarthritis and Rheumatoid Arthritis with a high risk of cardiovascular disease comparing the efficacy and safety of a study medication with other study medications.

Clearwater : Clinical Research of West Florida

Bothered by Arthritis? Concerned About Heart Disease?

Clearwater : Clinical Research of West Florida, Inc.

Volunteers Needed

Debary : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Fort Myers : Clinical Physiology Associates

Collection of Blood Samples

Fort Myers : Clinical Physiology Associates

Rheumatoid Arthritis

Jupitor : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Miami : Pharmax Research Clinic, Inc.

Rheumatoid Arthritis

Rock Island : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

St. Petersburg : Comprehensive Clinical Development, St. Petersburg

Rheumatoid Arthritis

Tampa : Clinical Research of West Florida, Inc.

Bothered by Arthritis? Concerned About Heart Disease?

West Palm Beach : Palm Beach Research Center

Bothered by Arthritis? Concerned about Heart Disease?

West Palm Beach : Metabolic Research Institute, Inc.

We are conducting a clinical research study to test the safety and effectiveness of an investigational medication in patients with rheumatoid arthritis (RA) who were previously unsuccessfully treated with another medication called a tumor necrosis factor-alpha (TNF-a) inhibitor.

View More »

Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Aventura :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Aventura : 142

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Boca Raton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Boca Raton : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Brandon : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Brandon : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Coral Springs :

An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)

Daytona Beach : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Daytona Beach : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Daytona Beach : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Debary : 151 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Dunedin : Investigational Site Number 840050 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Edgewater : Riverside Clinical Research

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Fort Lauderdale : 190

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Gainesville : University of Florida

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Jacksonville : Site Reference ID/Investigator# 38687

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Jacksonville : 173

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Jacksonville : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Jacksonville : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Jacksonville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Jacksonville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Jacksonville : Investigational Site Number 840041 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Jupiter : 196

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Jupiter : Investigational Site Number 840067 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Jupiter : 114 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Largo : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Melbourne :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Miami : Global Clinical Professionals

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Miami :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Miami : Site Reference ID/Investigator# 40105

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Miami : 232

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Miami : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Miami : Investigational Site Number 840048 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Naples : 213

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

New Port Richey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

New Port Richey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

North Miami Beach : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Ocala : 214

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Ocala : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Ocala : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Ocala : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ocala : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Orlando :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Orlando : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Orlando : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Orlando : Investigational Site Number 840006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Orlando : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Ormond Beach : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Ormond Beach : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Palm Harbor :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Palm Harbor : The Arthritis Center

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Palm Harbor : 163

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Palm Harbor : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Palm Harbor : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Palm Harbor : Investigational Site Number 840063 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Pinellas Park : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Pinellas Park : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Pinellas Park : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Plantation : 166

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Sarasota : Site Reference ID/Investigator# 38083

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Sarasota : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Sarasota : Investigational Site Number 840060 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Sarasota : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Sarasota : Sarasota Arthritis Research Center

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

South Miami : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

St Petersburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

St Petersburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

St. Petersburg : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Summerfield : Lakeview Medical Research

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tampa : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tampa : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Tampa : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Tampa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tampa : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Tampa : 157 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Tampa : 183 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Tampa : Florida Orthopaedic Institute

Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)

Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Venice : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Venice : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Vero Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Vero Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Vero Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Vero Beach : 200

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Vero Beach : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Zephyr Hills : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Zephyr Hills : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Zephyrhills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Zephyrhills :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Zephyrhills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Georgia

Alpharetta : CSI Research Inc

(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

Alpharetta : CSI Research Inc

A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis

Alpharetta : CSI Research Inc

A Phase 3 Study Comparing 2 Doses of study drug vs. Placebo for Treatment of Rheumatoid Arthritis

Alpharetta : CSI Research Inc

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

Gainesville : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Newnan : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Stockbridge : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Atlanta : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Atlanta : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Atlanta : Investigational Site Number 840003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Atlanta : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Canton : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Canton : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Canton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Decatur : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Decatur : Investigational Site Number 840028 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Duluth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Dunwoody : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Dunwoody : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Lawrenceville : Site Reference ID/Investigator# 38688

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Macon : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Macon : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Marietta : Investigational Site Number 840027 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Savannah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Savannah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Savannah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Stockbridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Stockbridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Stockbridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Idaho

Meridian : Advanced Clinical Research, ID

Bothered by Arthritis? Concerned about Heart Disease?

View More »

Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Coeur D'alene : 226

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Coeur D'alene : 145

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Idaho Falls :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Idaho Falls : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Idaho Falls : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Idaho Falls : Investigational Site Number 840018 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Idaho Falls : 116 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Meridian : Site Reference ID/Investigator# 38689

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Meridian : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Illinois

Moline : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Springfield : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Chicago : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Chicago : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Chicago : Investigational Site Number 840046 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Decatur : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Glendale : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Glenview : Illinois Bone & Joint Institute, Ltd.

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Maywood : Loyola University Medical Center

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Moline : 160 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Morton Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Morton Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Quincy : Quincy Medical Group

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Rock Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Rock Island : Site Reference ID/Investigator# 38085

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Rock Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Rock Island : 219

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Rockford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Rockford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Rockford : Rockford Orthopedic Associates, Ltd.

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Rockford : Rockford Orthopedics Associates

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Springfield : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Springfield : Site Reference ID/Investigator# 40128

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Springfield : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Springfield : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Springfield : 168 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Indiana

Bloomington : Bloomington Bone and Joint Clinic

Ascension® MCP Post-Approval Study

Brownsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Brownsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Evansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Evansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

View More »

Evansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Fort Wayne : Parkview Health

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

South Bend : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

South Bend : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

South Bend : Saint Joseph Regional Medical Center

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Terre Haute : 222

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Iowa

Cedar Rapids : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Bettendorf : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Cedar Rapids :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Cedar Rapids : 215

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Cedar Rapids : 133 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Kansas

Kansas City : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Wichita : Wichita Clinic, PA

Clinical Research Trial studying Rheumatoid Arthritis Therapy and Vaccines

Wichita : Wichita Clinic, PA

Have you been diagnosed with Rheumatoid Arthritis.

Wichita : Wichita Clinic, PA

Have you been diagnosed with Rheumatoid Arthritis?

View More »

Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kansas City : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Kansas City : University of Kansas Medical Center

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Lenexa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Shawnee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Wichita : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Wichita : 191

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wichita : 210

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Witchita : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kentucky

Lexington : University of Kentucky Chandler Medical Center

Have You Been Prescribed a New Medicine for Rheumatoid Arthritis?

Lexington : Kentucky Medical Research Center

Rheumatoid Arthritis

View More »

Bowling Green : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Bowling Green : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bowling Green : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Bowling Green : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Bowling Green : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Bowling Green : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Elizabethtown : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Elizabethtown : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Elizabethtown : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Lexington :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Lexington : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lexington : Investigational Site Number 840015 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lexington : Saint Joseph East Hospital

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Lexington : 134

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Louisville : Norton Orthopaedic Specialists

Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty

Owensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Owensboro : Trial Concierge

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Owensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Louisiana

Covington : Site Reference ID/Investigator# 38086

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Monroe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Monroe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Monroe : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Maryland

Cumberland : The Osteoporosis & Clinical Trials Center

A randomized, double-blind study of the effect of ocrelizumab in combination with methotrexate, compared to methotrexate alone, on the treatment response in methotrexate-naive patients with active rheumatoid arthritis.

Cumberland : The Osteoporosis & Clinical Trials Center

A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate

Towson : Spectrum Clinical Research, Inc.

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)

Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD

A phase 3B, Open-label, Multicenter, Exploratory study to assess changes in Joint Inflammation using ultrasonography in subjects with Rheumatoid Arthritis treated for 12 weeks with Certolizumab Pegol.

Wheaton : The Center for Rheumatology and Bone Research

A 2 arm study to evaluate Tocilizumab IV vs Enbrel SQ for 5 years

Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD

A randomized , double-blind, placebo-controlled , multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of IL-6Ra mAb on top of methotrexate in patients with active rheumatoid arthritis who are inadequate responders of MTX therapy.

Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD

A randomized, double-blind, parallel-group study of Cardiovascular safety in Osteoarthritis or Rheumatoid Arthritis patients with or at high risk for Cardiovascular disease comparing Celecoxib with Naproxen and Ibuprofen.

Wheaton : The Center for Rheumatology and Bone Research

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD

Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis

Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD

Phase 3b Golimumab Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients who have Inadequate disease control despite treatment with Etanercept (Enbrel) or Adalimumab (Humira)

View More »

Baltimore : Union Memorial Hospital

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Baltimore : 218

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Baltimore : Sinai Hospital of Baltimore

Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)

Crofton : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Crofton : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Cumberland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Cumberland :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Cumberland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Cumberland : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Cumberland : Investigational Site Number 840073 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Cumberland : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Frederick : Investigational Site Number 840055 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Frederick : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Hagerstown : 177

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hagerstown : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hagerstown : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Oxon Hill : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Wheaton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Wheaton :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Wheaton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Wheaton : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Wheaton : Investigational Site Number 840013 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Massachusetts

Hyannis : Clinical Research Center of Cape Cod, Inc

Do you have Osteoarthritis or Rheumatoid Arthritis and are at High Risk for Cardiovascular Disease?

View More »

Boston : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Boston : Brigham and Women's Hospital

Patient Rheumatoid Arthritis Social Support Study

Boston : Brigham and Women's Hospital

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Fall River : Site Reference ID/Investigator# 40125

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Fall River : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hyannis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Newton : Inflexxion, Inc.

Web-based Support to Manage Arthritis Pain

Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Worcester :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Worcester : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Worcester : Clinical Pharmacology Study Group

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Worcester : University of Massachusetts Medical School

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Michigan

Bingham Farms : QUEST Research Institute

Rheumatoid Arthritis Study of an Investigational Therapy for People Taking Methotrexate

View More »

Battle Creek : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Battle Creek :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Battle Creek : 137

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Bingham Farms : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Bingham Farms : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Bingham Farms : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

East Lansing : Mid Michigan Orthopaedic Institute

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Grand Rapids : Orthopaedic Associates of Michigan, PC

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Kalamazoo : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Kalamazoo : 199

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Kalamazoo : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Kalamazoo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lansing : 155

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Petoskey :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

St Clair Shores : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

St Clair Shores : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

St Clair Shores : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

St. Clair Shores : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Minnesota

Mississippi

Biloxi :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Flowood :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

View More »

Flowood :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Flowood : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Flowood : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Flowood : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Jackson : Arthritis Associates Of Mississippi

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Tupelo :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Missouri

St. Louis : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

St. Louis : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Cape Girardeau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Cape Girardeau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Cape Girardeau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Florissant : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Florissant : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Florissant : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Florissant : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Richmond Heights : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Richmond Heights : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Richmond Heights : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Richmond Heights : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

St Louis :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

St Louis : 134 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

St. Louis : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

St. Louis : 179

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

St. Louis : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

St. Louis : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

St. Louis : Investigational Site Number 840066 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

St. Louis : 112 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Montana

Nebraska

Lincoln : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Lincoln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Lincoln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lincoln : 181

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Lincoln : 102 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Omaha : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Omaha : Quality Clinical Research, Inc.

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Omaha : Investigational Site Number 840071 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Omaha : 135

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Nevada

Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Las Vegas : Advanced BioMedical Research of America

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

View More »

Las Vegas : Desert Orthopaedic Center

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Las Vegas : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Reno : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

New Hampshire

Lebanon : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Lebabon :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Nashua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Nashua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Nashua : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

New Jersey

Freehold : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

New Brunswick : UMDNJ-Robert Wood Johnson Medical School

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

New Brunswick : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Tom's River : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Berkeley Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Berkeley Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Clifton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Clifton : Site Reference ID/Investigator# 40124

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Clifton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Egg Harbor Township : Rothman Institute Updated

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Egg Harbor Township : The Rothman Institute Updated

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Freehold : Site Reference ID/Investigator# 38978

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Freehold : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Freehold : 171 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Manalapan :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Newark : University of Medicine & Dentistry of New Jersey

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Toms River : 152 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Voorhees : Site Reference ID/Investigator# 40123

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

New Mexico

Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Albuquerque : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

View More »

Albuquerque : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Las Cruces : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Las Cruces : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Las Cruces : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

New York

Albany : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Brooklyn : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Lake Success : Biomedical Research Alliance of New York

Rheumatoid Arthritis - Adults

Mineola : Winthrop University Hospital Clinical Trials Center

Rheumatoid Arthritis

New York : The Rockefeller University Hospital

Evaluation of Immune Activation in Rheumatoid Arthritis

Rochester : AAIR Research Center

A Open-Label Study to Evaluate the Safety of Administering Rituxan (Rituximab) at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis.

Rochester : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Rochester : Rochester Clinical Research

Rheumatoid Arthritis

Rochester : AAIR Research Center

Rheumatoid Arthritis Study

View More »

Albany : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Albany : 154

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Bronx : Site Reference ID/Investigator# 38983

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Brooklyn : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Brooklyn :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Brooklyn : 176

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brooklyn : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Brooklyn : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Brooklyn : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Brooklyn : 174 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Brooklyn : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Brooklyn : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Brooklyn : 136

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

New Rochelle : Sound Shore Medical Center of Westchester

Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)

New York :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

New York : Hospital for Special Surgery

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

New York : Investigational Site Number 840056 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

New York City : Kenneth Mroczek, MD-NYU

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Olean : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Olean : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Orchard Park :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Plainview :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Rochester : University of Rochester Medical Center

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Rochester : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Rochester : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Rochester : Lattimore Orthopaedics P.C.

Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)

Roslyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Roslyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Roslyn : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Roslyn : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Smithtown :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Smithtown : Site Reference ID/Investigator# 38264

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Smithtown : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Smithtown : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Syracuse : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

North Carolina

Cary : PMG Research of Cary

ARTHRITIS AND HEART DISEASE: Research Study

Charlotte : PMG Research of Charlotte

ARTHRITIS AND HEART DISEASE: Research Study

Charlotte : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Hickory : PMG Research of Hickory

ARTHRITIS AND HEART DISEASE: Research Study

Hickory : PMG Research of Hickory

Do you suffer from moderated to severe rheumatoid arthritis?

Hickory : PMG Research of Hickory

Do you take Methotrexate for you Rheumatoid Arthritis?

Hickory : PMG Research of Hickory

Have you been taking Methotrexate for at least 3 months for your Rheumatoid Arthritis?

Raleigh : PMG Research of Raleigh

ARTHRITIS AND HEART DISEASE: Research Study

Salisbury : PMG Research of Salisbury

ARTHRITIS AND HEART DISEASE: Research Study

Salisbury : PMG Research of Salisbury

Do you Have Rheumatoid Arthritis?

Wilmington : PMG Research of Wilmington

ARTHRITIS AND HEART DISEASE: Research Study

Winston-Salem : PMG Research of Winston-Salem

ARTHRITIS AND HEART DISEASE: Research Study

View More »

Asheville : Site Reference ID/Investigator# 38263

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Asheville : Mission Health System

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Belmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Charlotte : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Charlotte :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Charlotte : OrthoCarolina, PA

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Charlotte : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Charlotte : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Charlotte : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Charlotte : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Charlotte : 170 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Charlotte : Box Arthritis And Rheumatology Of The Carolinas, Pllc

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Charlotte : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Durham : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Durham : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Durham : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Durham : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Durham : Michael Bolognesi, MD

INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation

Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Greensboro : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Greensboro : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Greenville : Site Reference ID/Investigator# 38261

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Hickory : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Hickory : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hickory : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Hickory : Investigational Site Number 840068 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Salisbury : PMG Research of Salisbury

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Sanford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Sanford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Sanford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Washington :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Wilmington : Carolina Arthritis Associates

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Winston-salem : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

North Dakota

Ohio

Akron : Radiant Research - Akron

Rheumatoid Arthritis Research Study

Cincinnati : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Cleveland : Rapid Medical Research, Inc. (RMR)

Do you suffer from arthritis pain?

Columbus : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Dayton : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Akron :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Akron : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Cincinnati : 150 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Cincinnati : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Cincinnati : 140

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Cleveland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Cleveland : Cleveland Clinic Orthopaedic

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Columbus :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Columbus : Orthopedic Foot & Ankle Center

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Dayton : Providence Health Partners

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Dayton :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Dayton : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Dayton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Dayton : 100 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Gallipolis : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kettering : Kettering Health Network

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Mayfield Village : Site Reference ID/Investigator# 39024

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Mayfield Village : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Mayfield Village : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Middleburg Heights : Paramount Medical Research & Consulting, LLC

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Middleburg Heights :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Middleburg Heights : Paramount Medical Research & Consulting, Llc

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Perrysburg : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Perrysburg : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Perrysburg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Perrysburg : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Toledo : Zalicus Investigational Site

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Toledo : Investigational Site Number 840044 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Oklahoma

Oklahoma City : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Oklahoma City : Bone and Joint Hospital at St. Anthony

Rheumatoid Arthritis Research Study

Oklahoma City : Bone and Joint Hospital at St. Anthony

Rheumatoid Arthritis
The Flex-V Study

View More »

Norman :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Oklahoma City :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Oklahoma City : Site Reference ID/Investigator# 40127

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Oklahoma City : Health Research Institute, Inc.

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Oklahoma City : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Oklahoma City : Investigational Site Number 840002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Oklahoma City : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Oklahoma City : 110 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Oklahoma City : Health Research Of Oklahoma

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tulsa : Investigational Site Number 840011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Tulsa : Investigational Site Number 840065 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Oregon

Bend : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Bend : Site Reference ID/Investigator# 38202

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Bend : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bend : The Center

Ascension® MCP Post-Approval Study

Eugene : Site Reference ID/Investigator# 39023

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

View More »

Lake Oswego : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Lake Oswego : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lake Oswego : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Portland : Novatis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Portland : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Salem : Willamette Orthopedic Group LLC

Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)

Pennsylvania

Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bethlehem : Investigational Site Number 840010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bethlehem : East Penn Rheumatology Associates, P.C.

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

View More »

Ducansville : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Duncansville : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Duncansville : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Duncansville :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Duncansville : Site Reference ID/Investigator# 38265

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Duncansville : Research Site

Effects of Denosumab on the Pharmacokinetics of Etanercept

Duncansville : 167

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Duncansville : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Duncansville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Duncansville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Duncansville : Investigational Site Number 840009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Duncansville : 165 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Duncansville : Altoona Center For Clinical Research

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Duncansville : Altoona Center For Clinical Research

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Duncansville : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Duncansville : 132

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Erie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Erie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Erie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Erie : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Limerick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Limerick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Limerick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Philadelphia : University of Pennsylvania Health Systems-PA Foot and Ankle Surgeons

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Philadelphia :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Philadelphia : The Rothman Institute

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Philadelphia : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Philadelphia : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Philadelphia : Rothman Institute Updated

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Philadelphia : The Rothman Institute Updated

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Phoenixville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Pittsburgh : University of Pittsburgh - Oakland Falk Clinic

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Reading : Investigational Site Number 840062 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Souderton :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Waxford : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Waxford : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Waxford : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

West Reading :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

West Reading : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

West Reading : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Wexford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Wexford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Willow Grove :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Willow Grove : 220

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wynnewood :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Wyomissing : 168

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Rhode Island

South Carolina

Greer : Radiant Research - Greer

Rheumatoid Arthritis Research

Mt Pleasant : PMG Research of Charleston

ARTHRITIS AND HEART DISEASE: Research Study

Rock Hill : Carolinas Research Associates

Bothered by Arthritis? Concerned About Heart Disease?

View More »

Charleston :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Charleston : 189

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Charleston : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Charleston : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Charleston : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Columbia : Investigational Site Number 840058 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Greenville : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Greenville : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Greenville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Greer : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

North Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

North Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

North Charleston : Investigational Site Number 840016 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Orangeburg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Simpsonville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Taylors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Taylors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Taylors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

South Dakota

Tennessee

Bristol : PMG Research of Bristol

ARTHRITIS AND HEART DISEASE: Research Study

Nashville : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Hendersonville : 204

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hixson : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hixson : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Jackson : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Jackson :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Jackson :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Jackson : Site Reference ID/Investigator# 38082

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Jackson : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Jackson : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Jackson : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Jackson : Investigational Site Number 840025 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Jackson : 133

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Johnson City : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Knoxville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Knoxville : 160

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Memphis : Campbell Clinic / InMotion Orthopaedic Research Center

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Memphis : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Memphis : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Memphis : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Memphis : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Nashville : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Nashville : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Nashville : 105 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Texas

Amarillo : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Austin : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Dallas : Metroplex Clinical Research Center

A Multicenter, Randomized, Double-Period, Double-Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rheumatoid Arthritis

Dallas : Metroplex Clinical Research Center

A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF therapy.

Dallas : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Houston : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Houston : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Houston : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Houston : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Houston : DynaMed Clinical Research

Osteoarthritis or Rheumatoid Arthritis - Houston, TX

Houston : DM Clinical Research

Rheumatoid Arthritis

Mesquite : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

Nassau Bay : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

San Antonio : Sun Research Institute

Are you taking Humira or Cimzia? Have you taken these medications within the past 90 days?

San Antonio : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

San Antonio : Sun Research Institute

Rheumatoid Arthritis in people taking Methotrexate

San Antonio : Sun Research Institute

Rheumatoid Arthritis with poor response to Methotrexate?

Victoria : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Allen : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Amarillo : 185

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Amarillo : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Amarillo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Austin : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Austin : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Austin : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Austin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Austin : 135 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Carrollton :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Corpus Christi :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Corpus Christi : 178

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Corpus Christi : 151

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Dallas : Charles E. Cook, MD

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Dallas : Site Reference ID/Investigator# 37980

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Dallas : Site Reference ID/Investigator# 44888

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Dallas : Texas Health Research & Education Institute

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Dallas : Research Site

Effects of Denosumab on the Pharmacokinetics of Etanercept

Dallas : 162

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Dallas : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Dallas : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Dallas : Investigational Site Number 840001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Dallas : Investigational Site Number 840022 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Dallas : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Dallas : 128 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Dallas : 131

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Dallas : 146

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Houston : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Houston : Site Reference ID/Investigator# 43050

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Houston : Fondren Orthopedic Group

Ascension® MCP Post-Approval Study

Houston : St. Luke's Episcopal Hospital

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Houston : 206

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Houston : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Houston : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Houston : Investigational Site Number 840020 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Houston : 132 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Houston : 138 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Houston : 126 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Houston : 181 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Houston : Memorial Bone and Joint Clinic

Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)

Houston : Texas Orthopedic Hospital

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Lake Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Lake Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lubbock : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lubbock : Investigational Site Number 840069 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lubbock : Research Site

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Mesquite : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Mesquite :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Mesquite :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Mesquite : 158

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Mesquite : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Mesquite : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Mesquite : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mesquite : Investigational Site Number 840074 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Mesquite : 145 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Nassau Bay :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Nassau Bay : 175

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Nassau Bay : 143 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

North Richard Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

North Richland Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

North Richland Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Plano : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

San Antonio : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

San Antonio : Novartis Investigative Site

A Biomarker Study of Secukinumab in Rheumatoid Arthritis Patients

San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

San Antonio : Site Reference ID/Investigator# 43735

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

San Antonio : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

San Antonio : 197

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Antonio : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

San Antonio : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

San Antonio : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Antonio : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

San Antonio : 122 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

San Antonio : 139

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Sugar Land :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Sugarland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Sugarland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Sugarland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Victoria : 142 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Victoria : 165

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Waco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Waco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Utah

West Jordan : Advanced Clinical Research, UT

There's a new clinical study for people who have arthritis and are also at risk for heart disease.

View More »

Salt Lake City : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Vermont

Virginia

Arlington :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Chesapeake : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Chesapeake : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

View More »

Chesapeake : 139 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Richmond : Site Reference ID/Investigator# 44344

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Williamsburg : The Center for Excellence in Aging and Geriatric Health

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Washington

Seattle : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Kennewick : Apex Clinical Research

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Olympia : South Puget Sound Clinical Research Center

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension

Seattle : Site Reference ID/Investigator# 38542

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Seattle : Site Reference ID/Investigator# 40210

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Seattle : Site Reference ID/Investigator# 38084

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Seattle :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Seattle : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Seattle : Seattle Rheumatology Associates

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Seattle : University of Washington Medical Center

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Spokane :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Spokane : Site Reference ID/Investigator# 38424

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Spokane : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Spokane : 157

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tacoma :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Tacoma : Site Reference ID/Investigator# 38203

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tacoma : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Tacoma : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tacoma : Investigational Site Number 840061 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Tacoma : 175 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

West Virginia

Clarksburg : Center Location:

Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?

View More »

Beckley : 136 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Clarksburg : Vertex Investigational Site Updated

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Clarksburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Clarksburg :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Clarksburg : Investigational Site

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Clarksburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Clarksburg : 183

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Clarksburg : 167 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Wisconsin

Franklin : Site Reference ID/Investigator# 38087

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Glendale :

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Glendale : 174

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

La Crosse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Milwaukee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

View More »

Milwaukee : Medical College of Wisconsin

Ankle Joint Replacement Outcomes Study

Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Argentina

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Buenos Aires : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

View More »

Buenos Aires : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Buenos Aires : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Buenos Aires : Investigational Site Number 032005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Buenos Aires : Investigational Site Number 032007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Buenos Aires : Investigational Site Number 032008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Buenos Aires : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Caba : Investigational Site Number 032006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Capital Federal : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Ciudad Autonoma Bs As : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Ciudad Autonoma Bs As : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Cordoba : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Cordoba : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Cordoba : Investigational Site Number 032002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Cordoba : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Córdoba : Investigational Site Number 032003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lujan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Lujan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Lujan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Mar Del Plata : Investigational Site Number 032012 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Mendoza :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Quilmes :

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Quilmes : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Quilmes : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Quilmes : Investigational Site Number 032011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Ramos Mejia : Investigational Site Number 032010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Rosario : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Rosario : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Rosario : Investigational Site Number 032001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Rosario : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

San Isidro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

San Isidro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

San Juan : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

San Juan : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Juan : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

San Miguel de Tucuman : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

San Miguel de Tucuman : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Miguel De Tucuman : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tucuman : Investigational Site Number 032004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Tucuman : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Zarate : Investigational Site Number 032009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Australia

Adelaide :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Cairns : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Cairns : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Campbelltown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Campbelltown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

View More »

Camperdown : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Camperdown : Investigational Site Number 036003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Clayton : Investigational Site Number 036005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Coffs Harbour : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Dulwich : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Fitzroy : Investigational Site Number 036012 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Garran : Investigational Site Number 036010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Heidelberg : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Heidelberg West : Investigational Site Number 036004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Herston : Investigational Site Number 036009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Hobart :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Malvern : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Malvern East : Site Reference ID/Investigator# 63354

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Maroochydore : Site Reference ID/Investigator# 63355

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Maroochydore : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Maroochydore : Investigational Site Number 036001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Shenton Park : Site Reference ID/Investigator# 63353

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Southport : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

St Leonards : Investigational Site Number 036006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Sydney : Investigational Site Number 036011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Victoria Park : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Woodville :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Woodville : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Woodville : Investigational Site Number 036007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Austria

Graz : Investigational Site Number 040001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Innsbruck :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Vienna : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Wien :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Wien : 50

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Wien : Investigational Site Number 040002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Belarus

Belarus Site Information : Merck Sharp & Dohme IDEA, Inc.

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM2 EXT 1)

Belgium

Aalst : Site Reference ID/Investigator# 4791

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Aalst : Site Reference ID/Investigator# 4811

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Aalst : Site Reference ID/Investigator# 4821

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Amel : Site Reference ID/Investigator# 28430

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Antwerp : Site Reference ID/Investigator# 4817

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

View More »

Antwerp : Site Reference ID/Investigator# 4830

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Arlon : Site Reference ID/Investigator# 4834

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Assebroek : Site Reference ID/Investigator# 4837

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Assebroek : Site Reference ID/Investigator# 4848

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ath : Site Reference ID/Investigator# 28454

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Audregnies : Site Reference ID/Investigator# 4773

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Baudour : Site Reference ID/Investigator# 4856

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Belsele : Site Reference ID/Investigator# 4810

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Bornem : Site Reference ID/Investigator# 28445

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Bruges : Site Reference ID/Investigator# 4842

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brugge : Algemeen Ziekenhuis Sint Jan

Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA)

Brussels : Site Reference ID/Investigator# 28448

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 28449

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 4766

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 4770

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Ref # / Investigator 4815

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Ref # / Investigator 62674

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 28439

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 4863

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 4797

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 28420

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : Site Reference ID/Investigator# 28405

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Brussels : 51

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brussels : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Brussels : 401 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Bruxelles :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Bruxelles : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Bruxelles : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Champion : Site Ref # / Investigator 57023

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Charleroi : Site Reference ID/Investigator# 28408

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Charleroi : Site Reference ID/Investigator# 28462

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Courcelles : Site Reference ID/Investigator# 28415

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Destelbergen : Site Reference ID/Investigator# 28433

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Dinant : Site Reference ID/Investigator# 4772

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Edegem :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Edegem : Site Reference ID/Investigator# 4847

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Eeklo : Site Reference ID/Investigator# 28421

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Flemalle : Site Reference ID/Investigator# 4798

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Forchies-la-Marche : Site Reference ID/Investigator# 4831

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Genk : Site Reference ID/Investigator# 4852

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk : Site Reference ID/Investigator# 28452

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk : Site Reference ID/Investigator# 4855

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk : Site Reference ID/Investigator# 4803

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk : Site Reference ID/Investigator# 28465

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk : Site Reference ID/Investigator# 4781

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk : Site Reference ID/Investigator# 4792

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Genk : Investigational Site Number 056003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Gent : Site Reference ID/Investigator# 28429

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Gent : 31

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Gent : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Gent : Universitair Ziekenhuis

Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

Gentbrugge : Site Reference ID/Investigator# 28424

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ghent : Site Reference ID/Investigator# 4857

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ghent : Site Reference ID/Investigator# 4827

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ghent : Site Reference ID/Investigator# 4778

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ghent : Site Reference ID/Investigator# 4807

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ghent : Site Reference ID/Investigator# 4822

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ghent : Site Reference ID/Investigator# 4864

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Ghent : Site Reference ID/Investigator# 63360

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

Gilly :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Gilly : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Gistel : Site Reference ID/Investigator# 4838

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Gistel : Site Ref # / Investigator 56987

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Godinne :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Gosselies : Site Reference ID/Investigator# 4763

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Gosselies : Site Reference ID/Investigator# 4799

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Halle : Site Reference ID/Investigator# 28441

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Hamme : Site Reference ID/Investigator# 4819

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Hasselt : Site Reference ID/Investigator# 4775

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Hasselt : Site Reference ID/Investigator# 4777

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Hasselt : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Heusy :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Hoboken : Site Reference ID/Investigator# 28428

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Kalmthout : Site Reference ID/Investigator# 4836

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Keerbergen : Site Reference ID/Investigator# 4796

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Kortrijk : Site Reference ID/Investigator# 4780

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Kortrijk : Site Reference ID/Investigator# 28453

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Kortrijk : Site Reference ID/Investigator# 28463

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Kortrijk : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Kortrijk : 36

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

La Louviere : Site Reference ID/Investigator# 4764

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

La Louviere : Site Reference ID/Investigator# 28418

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

La Louviere : Site Reference ID/Investigator# 4768

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

La Louviere : Site Reference ID/Investigator# 4786

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Lennik : Site Reference ID/Investigator# 4805

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Leuven : Site Reference ID/Investigator# 4814

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Leuven : Site Reference ID/Investigator# 4865

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Leuze-en-Hainaut : Site Reference ID/Investigator# 4809

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Libramont-Chevigny : Site Reference ID/Investigator# 4849

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Liege :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Liege : Site Reference ID/Investigator# 28425

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Liege : Site Reference ID/Investigator# 28407

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Liege : Site Reference ID/Investigator# 4841

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Liege : Site Reference ID/Investigator# 28419

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Liege : Site Reference ID/Investigator# 28451

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Liege : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Liege : 400 Updated

Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056

Liège : Investigational Site Number 056001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lier : Site Reference ID/Investigator# 4782

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Lobbes : Site Reference ID/Investigator# 4795

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Lokeren : Site Reference ID/Investigator# 4779

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Lommel : Site Reference ID/Investigator# 4808

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Maarkedaal : Site Reference ID/Investigator# 4789

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Malle : Site Reference ID/Investigator# 4839

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Marchienne-au-Pont : Site Reference ID/Investigator# 28436

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Mechelen : Site Reference ID/Investigator# 4801

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Mechelen : Site Reference ID/Investigator# 4844

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Merelbeke : Site Reference ID/Investigator# 4816

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Merksem : Site Reference ID/Investigator# 4806

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Merksem : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Mons : Site Reference ID/Investigator# 4804

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Mons : Site Reference ID/Investigator# 4840

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Mons : Site Reference ID/Investigator# 28440

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Montegnee : Site Reference ID/Investigator# 4820

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Montignies-sur-Sambre : Site Reference ID/Investigator# 4812

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Namur : Site Reference ID/Investigator# 4818

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Namur : Site Reference ID/Investigator# 4788

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Nazareth : Site Reference ID/Investigator# 4861

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Neupre : Site Reference ID/Investigator# 4765

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Oostende :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Oostende : Site Reference ID/Investigator# 28432

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Oudenaarde : Site Ref # / Investigator 56991

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Plainevaux : Site Reference ID/Investigator# 4794

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Profondeville : Site Reference ID/Investigator# 4850

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Putte : Site Reference ID/Investigator# 28464

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Roeselare : Site Reference ID/Investigator# 28442

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Roeselare : Site Ref # / Investigator 28443

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Sijsele : Site Reference ID/Investigator# 46462

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Sijsele : Site Reference ID/Investigator# 4833

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Sint-Niklaas : Site Reference ID/Investigator# 4784

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Tielt : Site Reference ID/Investigator# 28446

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Turnhout : Site Reference ID/Investigator# 28447

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Veldegem : Site Reference ID/Investigator# 4774

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Verviers : Site Reference ID/Investigator# 28437

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Verviers : Site Reference ID/Investigator# 4851

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Waremme : Site Reference ID/Investigator# 28427

Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Wilrijk :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Yvoir : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Yvoir : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Bosnia and Herzegovina

Banja Luka :

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)

Mostar : Sveučilišna klinička bolnica Mostar

Long Term Extension Study For SPM-005 Participants

Mostar : Sveučilišna klinička bolnica Mostar

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Sarajevo : Klinicki Centar Univerziteta, Reumatologija

Long Term Extension Study For SPM-005 Participants

Sarajevo : Klinicki Centar Univerziteta, Reumatologija

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Brazil

Campinas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Campinas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Campinas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Campinas : Investigational Site Number 076008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Campinas : Investigational Site Number 076012 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

View More »

Caxias Do Sul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Caxias Do Sul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Curitiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Curitiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Curitiba : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Curitiba : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Curitiba : Investigational Site Number 076001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Fortaleza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Fortaleza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Goiania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Goiania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Goiania :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Goiania : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Goiania : Investigational Site Number 076006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Juiz De Fora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Juiz De Fora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Juiz De Fora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Juiz De Fora : Investigational Site Number 076010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Porto Alegre : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Porto Alegre : Investigational Site Number 076004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Recife : Investigational Site Number 076007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Rio De Janeiro : Investigational Site Number 076005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Salvador : Investigational Site Number 076011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Sao Paulo : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Sao Paulo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Sao Paulo : Investigational Site Number 076002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Sao Paulo : Investigational Site Number 076003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Setor Oeste/Goiania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Vitoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Vitoria : Investigational Site Number 076013 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bulgaria

Burgas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Burgas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Burgas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Pleven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Pleven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

View More »

Pleven : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Pleven : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Plovdiv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Plovdiv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Plovdiv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Plovdiv : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Plovdiv : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Plovdiv : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Rousse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Rousse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Rousse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Ruse : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Sevlievo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Sevlievo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Sevlievo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Sevlievo : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Sevlievo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Sofia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Sofia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Sofia : Nycomed Investigational Site

A Trial to Evaluate the Safety and Tolerability of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis

Sofia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Sofia : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Sofia : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Sofia : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Varna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Varna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Veliko Tarnovo : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Veliko Tarnovo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Canada

Bowmanville : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Bowmanville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Bowmanville : Site Ref # / Investigator 47667

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Brampton :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Brampton : Site Reference ID/Investigator# 37506

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

View More »

Brampton : Site Reference ID/Investigator# 38057

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Brampton : Site Reference ID/Investigator# 37515

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Burlington :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Burlington : Investigational Site Number 124004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Burlington : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Burnaby : Site Ref # / Investigator 52149

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Calgary : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Calgary : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Calgary : Site Reference ID/Investigator# 37514

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Calgary : Site Reference ID/Investigator# 37504

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Calgary : Site Reference ID/Investigator# 37521

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Cranbrook : Site Reference ID/Investigator# 52154

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Downsview : Site Ref # / Investigator 58484

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Edmonton : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Edmonton : Site Reference ID/Investigator# 37536

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Edmonton : Site Reference ID/Investigator# 37505

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Edmonton : Site Reference ID/Investigator# 37520

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Edmonton : Site Reference ID/Investigator# 37535

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Edmonton : Site Ref # / Investigator 37541

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Fredericton : Site Reference ID/Investigator# 37503

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Fredericton : Site Reference ID/Investigator# 37525

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Guelph : Site Reference ID/Investigator# 38063

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Halifax : Queen Elizabeth II Health Services

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Hamilton : Site Reference ID/Investigator# 67105

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Hamilton :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Hamilton : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hamilton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hamilton : Site Ref # / Investigator 55124

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Hamilton : Site Reference ID/Investigator# 47662

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Hamilton : Site Reference ID/Investigator# 38060

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Hamilton : Site Reference ID/Investigator# 38068

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Kamloops : Site Reference ID/Investigator# 38062

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Kamloops : Site Ref # / Investigator 54102

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Kamloops : Isis Investigational site

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Kelowna : Site Reference ID/Investigator# 52152

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Kitchener :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Kitchener :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Kitchener : Site Reference ID/Investigator# 37526

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Kitchener : Site Ref # / Investigator 55123

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Laval : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Laval : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Laval : Site Reference ID/Investigator# 47674

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Lethbridge : Site Reference ID/Investigator# 37516

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Levis : Site Reference ID/Investigator# 64043

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

London :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Lunenburg : Site Reference ID/Investigator# 47670

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Mississauga :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Mississauga : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Mississauga : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mississauga : Investigational Site Number 124003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Mississauga : Site Reference ID/Investigator# 37510

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Mississauga : Site Reference ID/Investigator# 37522

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Mississauga - Chow : Location n°31 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Montreal :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Montreal :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Montreal : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Montreal : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Montreal : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Montreal : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Montreal : Site Reference ID/Investigator# 37527

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Montreal : Site Reference ID/Investigator# 37539

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Montreal : Site Reference ID/Investigator# 47663

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Montreal : Site Reference ID/Investigator# 60122

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Montreal : Site Reference ID/Investigator# 37502

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Montreal : Site Reference ID/Investigator# 37537

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Montreal : Site Reference ID/Investigator# 37532

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Montreal : Isis Investigational Site

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Nanaimo : Site Reference ID/Investigator# 38069

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Nepean : Site Reference ID/Investigator# 37513

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Newmarket :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Newmarket : Investigational Site Number 124008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Newmarket : Site Reference ID/Investigator# 37542

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

North Vancouver : Site Reference ID/Investigator# 52148

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

North York : Site Ref # / Investigator 54103

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Ontario : Location n°36 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Ottawa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ottawa : Site Reference ID/Investigator# 37524

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Ottawa : Site Reference ID/Investigator# 38070

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Ottawa : Site Reference ID/Investigator# 37507

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Outremont : Site Reference ID/Investigator# 37523

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Penticton : Site Reference ID/Investigator# 38066

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Penticton : Site Reference ID/Investigator# 37538

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Peterborough : Site Reference ID/Investigator# 37529

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Prince George : Site Reference ID/Investigator# 47672

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Quebec : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Quebec : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Quebec City :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Quispamsis :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Rimouski :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rimouski :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Rimouski : Site Reference ID/Investigator# 47664

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Rimouski : Location n°34 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Sainte-foy :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Saint-Eustache : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Saskatchewan : Location n°33 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Saskatoon :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Scarborough : Site Reference ID/Investigator# 37518

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Sherbrooke : Site Reference ID/Investigator# 38059

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Sherbrooke : Site Ref # / Investigator 47676

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

St John's :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

St John's : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

St John's : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

St. Catharines :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

St. Catharines :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

St. Catharines : Investigational Site Number 124002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

St. Catharines : Site Reference ID/Investigator# 37534

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

St. Eustache : Site Reference ID/Investigator# 37528

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

St. John's : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

St. John's : Site Reference ID/Investigator# 37533

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

St. John's : Site Reference ID/Investigator# 37511

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

St. John's : Site Reference ID/Investigator# 37530

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Toronto : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Toronto : Investigational Site Number 124005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Toronto : Investigational Site Number 124001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Toronto : Site Reference ID/Investigator# 37508

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto : Site Reference ID/Investigator# 38058

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto : Site Reference ID/Investigator# 38065

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto : Site Reference ID/Investigator# 37509

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto : Site Reference ID/Investigator# 35722

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto : Site Reference ID/Investigator# 47668

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto : Site Reference ID/Investigator# 47678

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Toronto : Isis Investigational Site

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Toronto : Location n°35 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Trois-rivieres : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Trois-Rivieres : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Trois-Rivieres : Site Reference ID/Investigator# 47665

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Vancouver :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Vancouver : St. Paul's Hospital

Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Vancouver : University of British Columbia Hospital, Vancouver

Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty

Vancouver : University of British Columbia Hospital, Vancouver Updated

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Vancouver : Site Ref # / Investigator 52151

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Vancouver : Site Reference ID/Investigator# 37540

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Vancouver : Site Reference ID/Investigator# 43122

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Victoria : Site Reference ID/Investigator# 37517

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Victoria : Site Reference ID/Investigator# 37519

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Windsor :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Windsor : Site Reference ID/Investigator# 52147

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Winnipeg :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Winnipeg :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Winnipeg : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Winnipeg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Winnipeg : Investigational Site Number 124012 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Winnipeg : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Winnipeg : Site Reference ID/Investigator# 37512

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Winnipeg : Site Reference ID/Investigator# 54105

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Chile

Osorno : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Osorno : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Osorno : Investigational Site Number 152005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Puerto Montt : Investigational Site Number 152010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santiago : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

View More »

Santiago : Investigational Site Number 152011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santiago : Investigational Site Number 152012 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santiago : Investigational Site Number 152013 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santiago : Investigational Site Number 152008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santiago : Investigational Site Number 152009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santiago : Investigational Site Number 152001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Santiago : Investigational Site Number 152002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Valdivia : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Valdivia : Investigational Site Number 152004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Vina Del Mar : Investigational Site Number 152006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Viña Del Mar : Investigational Site Number 152007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

China

Baotou : The First Affiliated Hospital of Baotou Medical College

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Baotou city : Baotou Central Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Changsha : The Second Xiangya Hospital of Central South University

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Chengdu : Si Chuan Huaxi Hospital/Rheumatology Department

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Chongqing : Daping Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

View More »

Fuzhou : Fujian Provincial Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Guangzhou : The First Affiliated Hospital of Guangzhou University of Chinese Medicine

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Haerbin : No. 199

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Lanzhou : Lanzhou University Second Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Nanjing : Jiangsu Province Hospital/Department of Rheumatology

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Nantong : Affiliated Hospital of Nantong University

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Taiyuan : The Second Hospital of Shanxi Medical University

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Urumqi : Xinjiang Uygur Autonomous Region People's Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Colombia

Barranquilla :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Barranquilla : Investigational Site Number 170004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

View More »

Bogota :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bogota : Investigational Site Number 170001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bogota : Investigational Site Number 170008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bogota : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Bogotá : Investigational Site Number 170006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bucaramanga : Investigational Site Number 170007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bucaramanga : Investigational Site Number 170009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Chía : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Medellin : Investigational Site Number 170002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Medellin : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Croatia

Opatija : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Opatija : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Opatija : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Osijek : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Osijek : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

View More »

Rijeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Rijeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Rijeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Split : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Split : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Split : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Split : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Zagreb : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Zagreb : Sisters of Mercy Clinical Hospital Centre

Long Term Extension Study For SPM-005 Participants

Zagreb : Sisters of Mercy Clinical Hospital Centre

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Czech Republic

Brno : 108

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brno : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Brno : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Brno : Site Ref # / Investigator 55810

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Bruntal : Novartis Investigative site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

View More »

Bruntal : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Bruntal : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Bruntal : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ceske Budejovice : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Ceske Budejovice : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Chomutov : Site Ref # / Investigator 55807

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Hlucin : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hlucin : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Hlucin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hostivice : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Jihlava : Site Ref # / Investigator 55815

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Liberec : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Liberec : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Ostrava : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Ostrava : Novartis Investigational site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

Ostrava : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Ostrava : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ostrava - Trebovice : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Ostrava-trebovice : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Pardubice : Site Ref # / Investigator 55816

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Prague : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Praha : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Praha : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Praha : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Praha 1 : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Praha 11 - Chodov : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Praha 2 : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Praha 4 : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Sokolov : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Terezin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Uherske Hradiste : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Uherske Hradiste : Novartis Investigational site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

Uherske Hradiste : Site Ref # / Investigator 55814

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Uherské Hradiste : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Zlin : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Zlin : Novartis Investigative site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

Zlin : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Zlin : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Zlin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Zlin : Site Ref # / Investigator 55806

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Zlín : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Denmark

Ålborg :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Frederiksberg :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Frederiksberg : 003

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Hellerup : 002

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Hjorring : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

View More »

Holbæk :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Hvidovre : 001

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Odense :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Slagelse : 016

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Svendborg :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Estonia

Parnu : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tallinn : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tallinn : Investigational Site Number 233001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Tallinn : Investigational Site Number 233002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Tartu : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Finland

Hämeenlinna :

An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)

Helsinki :

An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)

Helsinki : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Helsinki : Investigational Site Number 246001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Helsinki : Helsinki University Central Hopsital

REstore Working Ability in RheumatoiD Arthritis

View More »

Hyvinkää :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Hyvinkää : Investigational Site Number 246002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Paimio :

An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)

Pori : Investigational Site Number 246003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Riihimäki :

A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

Rovaniemi : Lappland Central Hospital

REstore Working Ability in RheumatoiD Arthritis

Tampere :

An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)

Tampere : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Tampere : Tampere University hospital, Rheumatology Centre

REstore Working Ability in RheumatoiD Arthritis

Turku : The Turku Universitry Central Hopsital

REstore Working Ability in RheumatoiD Arthritis

France

Amiens :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Amiens : Location n°41 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Amiens Cedex : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Angers :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Annecy : Clinique Generale D'Annecy

Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

View More »

Bobigny : Location n°13 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Bordeaux Cedex : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Carcassonne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Chambray Les Tours : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Chambray Les Tours : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Creteil :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Dreux : Location n°39 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Evian Les Bains :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Frejus :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Grenoble : Location n°14 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Libourne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lille :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lomme :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Marseille : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Meaux : Location n°40 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Metz : Hospital Belle Isle

An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement

Metz Tessy :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Montpellier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Montpellier : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Montpellier Cedex 5 : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Nantes Cedex 1 : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Nevers :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Nice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Orleans : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Orleans Cedex 1 : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Paris :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Paris : Location n°25 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Paris (Hop Bichat) : Location n°37 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Paris Cedex 12 : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Paris Cedex 13 : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Paris Cedex 14 : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Perigueux :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Pierre Benite :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Poitiers : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Pontoise :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Reims : CHRU Reims Hôpital Maison Blanche

Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

Saint-Etienne Cedex 02 : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Saint-priest En Jarez :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

St Brieuc :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

St Herblain : Polyclinique de l'Atlantique

Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

St Nazaire :

Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)

Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Strasbourg : Location n°38 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Strasbourg Cedex : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Thionville :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Villeneuve St Georges :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Germany

Aachen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Aachen :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Aachen : Site Reference ID/Investigator# 35036

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Aachen : Site Reference ID/Investigator# 35033

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Aachen : Site Reference ID/Investigator# 35034

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

View More »

Aachen : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Aachen : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Achern : Site Reference ID/Investigator# 53919

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ahlen : Site Reference ID/Investigator# 35510

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ahlen : Site Reference ID/Investigator# 30699

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ahrensburg : Site Reference ID/Investigator# 35040

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ahrensburg : Site Reference ID/Investigator# 30726

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Aichhalden : Site Reference ID/Investigator# 53883

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Altenburg : Site Reference ID/Investigator# 35043

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Altenburg : Site Reference ID/Investigator# 35041

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Altenburg : Site Reference ID/Investigator# 30727

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Altenholz : Site Reference ID/Investigator# 35046

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Altenholz : Site Reference ID/Investigator# 51043

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Amberg : Site Reference ID/Investigator# 35049

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Amberg : Site Reference ID/Investigator# 53974

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Amberg : Site Reference ID/Investigator# 35050

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Amberg : Site Reference ID/Investigator# 30398

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Arnstadt : Site Reference ID/Investigator# 35057

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Arnstadt : Site Ref # / Investigator 53603

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Attendorn : Site Reference ID/Investigator# 35520

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Auerbach : Site Reference ID/Investigator# 30006

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Augsburg : Site Reference ID/Investigator# 33349

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Augsburg : Site Reference ID/Investigator# 33347

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Augsburg : Site Reference ID/Investigator# 30717

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Abbach : Site Reference ID/Investigator# 33358

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Abbach : Site Reference ID/Investigator# 33361

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Abbach : Site Reference ID/Investigator# 33359

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Abbach : Site Reference ID/Investigator# 33356

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Abbach : Site Reference ID/Investigator# 30714

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Aibling :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bad Aibling : Site Reference ID/Investigator# 35142

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Aibling : Site Reference ID/Investigator# 33362

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Aibling : Site Reference ID/Investigator# 35084

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Aibling : Site Reference ID/Investigator# 53968

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Bellingen : Site Reference ID/Investigator# 53966

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Bentheim : Site Reference ID/Investigator# 35523

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Brambach : Site Reference ID/Investigator# 35570

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Bramstedt :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bad Bramstedt : Site Reference ID/Investigator# 35573

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Bramstedt : Site Reference ID/Investigator# 53903

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Bramstedt : Site Reference ID/Investigator# 35571

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Bramstedt : Site Reference ID/Investigator# 49288

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Buchau : Site Reference ID/Investigator# 53929

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Doberan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Bad Doberan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bad Doberan : Site Ref # / Investigator 53610

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Endbach : Site Reference ID/Investigator# 33372

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Endbach : Site Reference ID/Investigator# 33369

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Endbach : Site Reference ID/Investigator# 33370

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Homburg : Site Ref # / Investigator 51066

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Iburg : Site Reference ID/Investigator# 33378

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Iburg : Site Reference ID/Investigator# 33382

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Iburg : Site Reference ID/Investigator# 33380

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Iburg : Site Reference ID/Investigator# 30422

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Iburg : Site Reference ID/Investigator# 30372

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Kissingen : Site Reference ID/Investigator# 33384

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Kreuznach : Site Reference ID/Investigator# 35575

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Kreuznach : Site Reference ID/Investigator# 33387

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Kreuznach : Site Reference ID/Investigator# 33385

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Kreuznach : Site Reference ID/Investigator# 30348

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Liebenwerda : Site Reference ID/Investigator# 33389

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Liebenwerda : Site Reference ID/Investigator# 30705

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Liebenwerda 04924 : Site Reference ID/Investigator# 33391

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Mergentheim : Site Reference ID/Investigator# 53942

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Muender : Site Reference ID/Investigator# 33396

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Muender : Site Reference ID/Investigator# 33394

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Nauheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Bad Nauheim :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bad Nauheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bad Nauheim : Site Ref # / Investigator 33398

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Nauheim : Investigational Site Number 276011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bad Nauheim : Site Ref # / Investigator 51073

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Neuenahr : Site Reference ID/Investigator# 35578

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Neuenahr : Site Reference ID/Investigator# 33399

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Neuenahr : Site Reference ID/Investigator# 35576

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Neuenahr : Site Ref # / Investigator 53611

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Neuenahr : Site Ref # / Investigator 53384

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Pyrmont : Site Reference ID/Investigator# 53980

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Rappenau : Site Reference ID/Investigator# 33404

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Rappenau : Site Reference ID/Investigator# 33402

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Salzungen : Site Reference ID/Investigator# 51883

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Soden-Salmuenster : Site Reference ID/Investigator# 33412

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Soden-Salmuenster : Site Reference ID/Investigator# 33410

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Staffelstein :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bad Staffelstein : Site Reference ID/Investigator# 33415

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Staffelstein : Site Reference ID/Investigator# 30334

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Toelz : Site Reference ID/Investigator# 54804

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bad Toelz : Site Reference ID/Investigator# 49263

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Toelz : Site Reference ID/Investigator# 49261

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Baden-Baden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Baden-Baden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Baden-Baden : Site Reference ID/Investigator# 33425

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Baden-Baden : Site Reference ID/Investigator# 33423

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Baden-Baden : Site Reference ID/Investigator# 30725

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bamberg : Site Reference ID/Investigator# 33429

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bamberg : Site Reference ID/Investigator# 33427

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bamberg : Site Reference ID/Investigator# 30324

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bautzen : Site Reference ID/Investigator# 33438

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bautzen : Site Reference ID/Investigator# 33436

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bautzen : Site Reference ID/Investigator# 30815

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bautzen : Site Reference ID/Investigator# 30330

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bayreuth :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bayreuth : Site Reference ID/Investigator# 33442

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bayreuth : Site Reference ID/Investigator# 33446

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bayreuth : Site Reference ID/Investigator# 33440

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bayreuth : Site Reference ID/Investigator# 30443

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bayreuth : Site Reference ID/Investigator# 30424

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Belm : Site Reference ID/Investigator# 53978

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bensheim : Site Reference ID/Investigator# 33449

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bensheim : Site Reference ID/Investigator# 29883

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Berlin :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Berlin :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Berlin :

An Observational Study on The Safety and Effectiveness of Mabthera (Rituximab) in The First Six Months of Treatment in Patients With Severe Active Rheumatoid Arthritis

Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Berlin : Study Site (Berlin 1)

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Berlin : Study Site (Berlin 2)

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Berlin : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Berlin : Site Reference ID/Investigator# 35597

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35089

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34246

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33620

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33648

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33661

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33683

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33687

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33693

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33641

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33658

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33670

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33690

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33697

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33704

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Ref # / Investigator 33674

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34238

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35527

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35550

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35551

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34269

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33662

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33672

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33685

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33695

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34243

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 53959

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 53884

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33646

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33681

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33688

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 53948

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 53933

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 53939

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 53971

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 53902

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35599

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35552

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34260

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin : Investigational Site Number 276008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Berlin : Investigational Site Number 276009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Berlin : Investigational Site Number 276010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Berlin : Investigational Site Number 276007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Berlin : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Berlin : Site Reference ID/Investigator# 29866

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 53385

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 49313

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30394

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30288

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30290

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30246

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 49253

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 64823

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 53406

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 64826

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator 30234

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 51050

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 51074

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 51108

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Ref # / Investigator 53387

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30396

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30707

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30462

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30218

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin :

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Berlin :

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Berlin-Buch : Site Reference ID/Investigator# 34266

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin-Buch : Site Reference ID/Investigator# 34264

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin-Buch : Site Ref # / Investigator 53608

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin-Wannsee : Site Reference ID/Investigator# 34252

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin-Wannsee : Site Reference ID/Investigator# 34250

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Berlin-Wannsee : Site Ref # / Investigator 53390

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bernau : Site Reference ID/Investigator# 35556

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bernau : Site Reference ID/Investigator# 35554

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bernau : Site Reference ID/Investigator# 30713

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Biberach : Site Reference ID/Investigator# 34277

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Biberach : Site Reference ID/Investigator# 53899

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bielefeld : Site Reference ID/Investigator# 34279

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bietigheim-Bissingen : Site Reference ID/Investigator# 35559

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bietigheim-Bissingen : Site Reference ID/Investigator# 35560

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bietigheim-Bissingen : Site Reference ID/Investigator# 49303

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Binzen : Site Reference ID/Investigator# 35562

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Blankenburg/Hart : Site Reference ID/Investigator# 34285

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Blankenburg/Hart : Site Reference ID/Investigator# 34283

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Blaubeuren :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Blaubeuren : Site Reference ID/Investigator# 34288

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Blaubeuren : Site Reference ID/Investigator# 34286

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Blaubeuren : Site Reference ID/Investigator# 30817

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bocholt : Site Reference ID/Investigator# 35566

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bocholt : Site Reference ID/Investigator# 34291

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bocholt : Site Reference ID/Investigator# 53946

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bocholt : Site Reference ID/Investigator# 34289

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bochum : Site Reference ID/Investigator# 35641

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bochum : Site Reference ID/Investigator# 35567

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bochum : Site Reference ID/Investigator# 49287

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bogen : Site Reference ID/Investigator# 35644

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bogen : Site Reference ID/Investigator# 35642

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bogen : Site Reference ID/Investigator# 30306

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bonn : Site Reference ID/Investigator# 34296

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 34302

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 35646

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bonn : Site Ref # / Investigator 34300

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 34294

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 53969

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 35647

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 35648

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 30279

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bonn : Site Reference ID/Investigator# 49302

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bonn : Site Ref # / Investigator 53404

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bottrop : Site Reference ID/Investigator# 35652

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Braunschweig : Site Reference ID/Investigator# 34307

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Braunschweig : Site Reference ID/Investigator# 34305

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Braunschweig : Site Reference ID/Investigator# 34310

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Braunschweig : Site Reference ID/Investigator# 49284

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Braunschweig : Site Reference ID/Investigator# 30264

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Breitenbrunn : Site Reference ID/Investigator# 35603

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Breitenbrunnd : Site Reference ID/Investigator# 35601

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bremen : Site Reference ID/Investigator# 35609

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bremen : Site Reference ID/Investigator# 35607

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bremen : Site Reference ID/Investigator# 53975

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Bremen : Site Reference ID/Investigator# 29875

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bruchhausen-vilsen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Buechen : Site Reference ID/Investigator# 53934

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Celle : Site Reference ID/Investigator# 35611

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Celle : Site Reference ID/Investigator# 34696

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Chemnitz :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Chemnitz : Site Reference ID/Investigator# 35093

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Chemnitz : Site Reference ID/Investigator# 34699

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Chemnitz : Site Reference ID/Investigator# 35092

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Chemnitz : Site Reference ID/Investigator# 34700

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Chemnitz : Site Reference ID/Investigator# 30284

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Chemnitz : Site Reference ID/Investigator# 29807

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Coesfeld : Site Reference ID/Investigator# 35615

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 35237

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 33989

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 33987

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 33996

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 33990

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 33993

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 35238

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Cologne : Site Ref # / Investigator 53409

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Cologne : Site Ref # / Investigator 53391

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Cottbus : Site Reference ID/Investigator# 34708

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cottbus : Site Reference ID/Investigator# 34711

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cottbus : Site Reference ID/Investigator# 35617

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Cottbus : Site Reference ID/Investigator# 30812

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Cottbus : Site Reference ID/Investigator# 30344

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Cuxhaven :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Cuxhaven : Site Reference ID/Investigator# 53889

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Cuxhaven : Site Reference ID/Investigator# 53987

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Damp : Site Reference ID/Investigator# 34718

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Damp : Site Reference ID/Investigator# 34715

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Damp : Site Reference ID/Investigator# 30780

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Darmstadt : Site Reference ID/Investigator# 35621

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Darmstadt : Site Reference ID/Investigator# 35622

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Darmstadt : Site Reference ID/Investigator# 30318

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Darmstadt : Site Reference ID/Investigator# 29983

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Deggendorf : Site Reference ID/Investigator# 34725

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Deggendorf : Site Reference ID/Investigator# 30382

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Delmenhorst : Site Reference ID/Investigator# 53885

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Demmin : Site Reference ID/Investigator# 34726

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Denkendorf : Site Reference ID/Investigator# 53932

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dessau-Rosslau : Site Reference ID/Investigator# 35631

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dessau-Rosslau : Site Reference ID/Investigator# 49272

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dortmund : Site Reference ID/Investigator# 34742

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dortmund : Site Reference ID/Investigator# 35634

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dortmund : Site Reference ID/Investigator# 35635

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dortmund : Site Reference ID/Investigator# 35632

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dortmund : Site Reference ID/Investigator# 35636

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Dresden :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 34760

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34748

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34751

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34754

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 35170

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34762

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34763

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 53958

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34749

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 35171

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 49244

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 49283

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 30256

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 30390

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 30703

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Duesseldorf : Site Reference ID/Investigator# 34773

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Duesseldorf : Site Reference ID/Investigator# 34768

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Duesseldorf : Site Reference ID/Investigator# 34774

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Duesseldorf : Site Reference ID/Investigator# 34771

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Duesseldorf : Site Reference ID/Investigator# 49278

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Duesseldorf : Site Ref # / Investigator 51107

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Duisburg : Site Reference ID/Investigator# 34778

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Duisburg : Site Reference ID/Investigator# 53897

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Duisburg : Site Ref # / Investigator 34776

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Duisburg : Site Reference ID/Investigator# 29813

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ebensfeld : Site Reference ID/Investigator# 34779

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Eberswalde : Site Reference ID/Investigator# 34784

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Eberswalde : Site Reference ID/Investigator# 34782

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Eberswalde : Site Reference ID/Investigator# 49290

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Eisenbergngen : Site Reference ID/Investigator# 54805

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Elmshorn : Site Reference ID/Investigator# 35184

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Elmshorn : Site Reference ID/Investigator# 35180

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Elmshorn : Site Reference ID/Investigator# 30298

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Emmerich : Site Reference ID/Investigator# 49258

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Erfstadt : Site Reference ID/Investigator# 34802

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Erfurt :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Erfurt : Site Reference ID/Investigator# 35191

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Erfurt : Site Reference ID/Investigator# 35096

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Erfurt : Site Reference ID/Investigator# 34809

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Erfurt : Site Reference ID/Investigator# 35189

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Erfurt : Site Reference ID/Investigator# 35097

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Erfurt : Site Reference ID/Investigator# 30722

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Erfurt : Site Reference ID/Investigator# 30364

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Erlangen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Erlangen :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Erlangen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Erlangen : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Erlangen : Site Reference ID/Investigator# 34821

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Erlangen : Site Ref # / Investigator 54811

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Erlangen : Site Reference ID/Investigator# 34815

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Erlangen : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Erlangen : Investigational Site Number 276004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Essen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Essen : Site Reference ID/Investigator# 35196

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 35199

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 53931

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 34823

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 35194

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 53925

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 49268

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Essen : Site Reference ID/Investigator# 30740

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Esslingen : Site Reference ID/Investigator# 34829

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Feldafing : Site Reference ID/Investigator# 35202

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Feldafing : Site Reference ID/Investigator# 35200

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Flensburg : Site Reference ID/Investigator# 35205

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Flensburg : Site Reference ID/Investigator# 35203

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Forchheim : Site Reference ID/Investigator# 34833

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Forchheim : Site Reference ID/Investigator# 34831

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Forchheim : Site Reference ID/Investigator# 30376

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankenberg : Site Reference ID/Investigator# 35210

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Frankenberg : Site Reference ID/Investigator# 30252

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Frankfurt :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Frankfurt : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Frankfurt : Site Reference ID/Investigator# 34840

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Frankfurt : Site Reference ID/Investigator# 34849

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Frankfurt : Site Reference ID/Investigator# 34843

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Frankfurt : Site Reference ID/Investigator# 34838

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Frankfurt : Site Reference ID/Investigator# 34851

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Frankfurt : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Frankfurt : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Frankfurt : Site Reference ID/Investigator# 30260

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 30248

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 49247

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 49286

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 49260

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt Am Main : Investigational Site Number 276003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Frankfurt am Main : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Fraureuth : Site Reference ID/Investigator# 35213

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Fraureuth : Site Reference ID/Investigator# 35211

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Freiberg : Site Reference ID/Investigator# 35219

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freiberg : Site Reference ID/Investigator# 35217

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Freiberg : Site Reference ID/Investigator# 30366

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Freiburg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Freiburg : Site Reference ID/Investigator# 34854

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freiburg : Site Reference ID/Investigator# 34861

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freiburg : Site Reference ID/Investigator# 35221

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freiburg : Site Reference ID/Investigator# 34852

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Freiburg : Site Reference ID/Investigator# 34855

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Freiburg : Site Reference ID/Investigator# 34859

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Freiburg : Site Reference ID/Investigator# 53926

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Freiburg : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Freiburg : Site Reference ID/Investigator# 49294

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Freiburg : Site Reference ID/Investigator# 51099

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Freiburg : Site Reference ID/Investigator# 29810

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Freystadt : Site Reference ID/Investigator# 35101

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freystadt : Site Reference ID/Investigator# 35099

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Friedberg : Site Reference ID/Investigator# 53960

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Friedrichroda : Site Reference ID/Investigator# 35224

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Friedrichroda : Site Reference ID/Investigator# 35222

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Friedrichroda : Site Ref # / Investigator 51047

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Geesthacht : Site Reference ID/Investigator# 53976

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Geesthacht : Site Reference ID/Investigator# 49307

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Geilenkirchen : Site Reference ID/Investigator# 53890

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Gelsenkirchen : Site Reference ID/Investigator# 34879

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Gelsenkirchen : Site Ref # / Investigator 34877

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Gera : Site Reference ID/Investigator# 34883

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

GieBen : Site Reference ID/Investigator# 34887

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Gielefeld : Site Ref # / Investigator 54810

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Giessen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Giessen : Site Reference ID/Investigator# 53909

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Gladbeck : Site Reference ID/Investigator# 53922

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Gladbeck : Site Reference ID/Investigator# 49273

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Goettingen : Site Ref # / Investigator 65622

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Goettingen : Site Reference ID/Investigator# 35231

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Gommern :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Gosheim : Site Reference ID/Investigator# 35491

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Goslar : Site Reference ID/Investigator# 34896

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Goslar : Site Reference ID/Investigator# 34894

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Göttingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Göttingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Grafelfing : Site Reference ID/Investigator# 30368

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Gräfelfing :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Greifswald : Site Reference ID/Investigator# 34904

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Greifswald : Site Reference ID/Investigator# 35496

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Greifswald : Site Reference ID/Investigator# 34901

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Greifswald : Site Reference ID/Investigator# 34902

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Greifswald : Site Reference ID/Investigator# 49259

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Greifswald : Site Reference ID/Investigator# 49256

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Greifswald : Site Reference ID/Investigator# 30328

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Guben : Site Reference ID/Investigator# 35498

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Guestrow : Site Reference ID/Investigator# 34910

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Guestrow : Site Reference ID/Investigator# 30404

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Gustrow : Site Reference ID/Investigator# 34912

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hagen : Site Reference ID/Investigator# 35503

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hagen : Site Reference ID/Investigator# 35501

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Halle :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Halle :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Halle : Site Reference ID/Investigator# 34937

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34940

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34922

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34932

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34944

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Ref # / Investigator 33819

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34924

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34920

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34935

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34938

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34942

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 30729

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Halle : Site Reference ID/Investigator# 30452

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 34955

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34958

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34970

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34983

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34994

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35441

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35449

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35111

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35444

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35452

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34952

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34961

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34974

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34986

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34998

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35000

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35007

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34946

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34959

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34965

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34977

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34984

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34996

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 33578

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35442

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35450

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 53984

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 54806

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Ref # / Investigator 34967

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 33367

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34956

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34962

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35112

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34981

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34989

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35001

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 53900

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hamburg : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hamburg : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hamburg : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Hamburg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hamburg : Investigational Site Number 276005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Hamburg : Frank Lampe, MD

Minimally Invasive Versus Conventional Approaches in Navigated Total Knee Arthroplasty (TKA)

Hamburg : Site Reference ID/Investigator# 30392

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30400

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30739

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30702

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30715

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30716

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30797

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30340

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30346

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30286

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30292

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49245

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30818

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30821

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49295

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49280

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49312

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 29833

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamm : Site Reference ID/Investigator# 53953

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hanau : Site Reference ID/Investigator# 35019

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hanau : Site Reference ID/Investigator# 35017

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hanau : Site Reference ID/Investigator# 30270

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hannover :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Hannover : Site Reference ID/Investigator# 35025

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hannover : Site Reference ID/Investigator# 33712

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hannover : Site Reference ID/Investigator# 33713

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hannover : Site Reference ID/Investigator# 35021

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hannover : Site Reference ID/Investigator# 35032

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hannover : Site Reference ID/Investigator# 33788

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hannover : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Hannover : Site Reference ID/Investigator# 30262

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hannover : Site Reference ID/Investigator# 30029

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hanover : Site Ref # / Investigator 53393

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Harrislee : Site Reference ID/Investigator# 33792

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Harrislee : Site Reference ID/Investigator# 33790

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Haseluenne : Site Reference ID/Investigator# 35459

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Haseluenne : Site Ref # / Investigator 65629

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hattingen : Site Reference ID/Investigator# 33795

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Heidelberg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Heidelberg :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Heidelberg : Site Reference ID/Investigator# 33798

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heidelberg : Site Reference ID/Investigator# 33808

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heidelberg : Site Reference ID/Investigator# 35119

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heidelberg : Site Reference ID/Investigator# 33801

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heidelberg : Site Reference ID/Investigator# 33813

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heidelberg : Site Reference ID/Investigator# 33806

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Heidelberg : Site Reference ID/Investigator# 33796

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Heidelberg : Site Reference ID/Investigator# 33811

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Heidelberg : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Heidelberg : Investigational Site Number 276012 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Heidelberg : Site Ref # / Investigator 53388

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Heidelberg : Site Reference ID/Investigator# 30254

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Heidelberg : Site Reference ID/Investigator# 30701

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Heidelberg : Site Reference ID/Investigator# 30448

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Heidelberg : Site Reference ID/Investigator# 30451

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Heidelberg : Site Reference ID/Investigator# 49282

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Heidenheim : Site Reference ID/Investigator# 35464

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heilbad Hailigenstadt : Site Reference ID/Investigator# 33816

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Heilbad Heiligenstadt : Site Reference ID/Investigator# 33818

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heilbad Heiligenstadt : Site Reference ID/Investigator# 49292

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Herne : Site Reference ID/Investigator# 53911

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Herne : Site Ref # / Investigator 65623

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Herne : Site Reference ID/Investigator# 53910

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Herne : Investigational Site Number 276001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Herne : Site Ref # / Investigator 53407

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Herrsching : Site Reference ID/Investigator# 33825

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Herrsching : Site Reference ID/Investigator# 33823

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Herrsching : Site Reference ID/Investigator# 30737

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hildesheim : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Hildesheim : Site Reference ID/Investigator# 33831

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hildesheim : Investigational Site Number 276006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Hildesheim : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Hildesheim : Site Reference ID/Investigator# 49308

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hof : Site Reference ID/Investigator# 33834

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hof : Site Reference ID/Investigator# 33836

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hofheim : Site Reference ID/Investigator# 33842

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hofheim : Site Reference ID/Investigator# 33840

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Hofheim : Site Reference ID/Investigator# 49285

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hohenfelde : Site Reference ID/Investigator# 33845

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hohenfelde : Site Reference ID/Investigator# 33843

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Homburg : Site Reference ID/Investigator# 54807

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

IIIertissen : Site Reference ID/Investigator# 33855

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Illingen : Site Reference ID/Investigator# 53985

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Immenstadt : Site Reference ID/Investigator# 33858

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Immenstadt : Site Reference ID/Investigator# 49252

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ingolstadt : Site Reference ID/Investigator# 35479

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ingolstadt : Site Reference ID/Investigator# 33933

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ingolstadt : Site Reference ID/Investigator# 29877

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Jena :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Jena : Site Reference ID/Investigator# 51882

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Jena : Site Reference ID/Investigator# 5323

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Jena : Site Reference ID/Investigator# 53938

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Jena : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Jena : Site Reference ID/Investigator# 49289

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Jena : Site Reference ID/Investigator# 49242

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Juelich : Site Reference ID/Investigator# 33940

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Juelich : Site Reference ID/Investigator# 49274

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Julich : Site Reference ID/Investigator# 33942

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Kahla : Site Reference ID/Investigator# 33946

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Kahla : Site Reference ID/Investigator# 35125

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Kahla : Site Reference ID/Investigator# 33944

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kahla : Site Reference ID/Investigator# 35124

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kahla : Site Reference ID/Investigator# 30453

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Kahla : Site Reference ID/Investigator# 30454

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Kaiserslautern : Site Reference ID/Investigator# 33950

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Kaiserslautern : Site Reference ID/Investigator# 33948

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kaiserslautern : Site Reference ID/Investigator# 69462

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Kaltenkirchen : Site Reference ID/Investigator# 53935

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Karlsruhe : Site Reference ID/Investigator# 33956

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Karlsruhe : Site Reference ID/Investigator# 33961

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Karlsruhe : Site Reference ID/Investigator# 33954

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Karlsruhe : Site Reference ID/Investigator# 33397

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Karlsruhe : Site Reference ID/Investigator# 30374

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Karlsruhe : Site Reference ID/Investigator# 30711

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Karlsruhe : Site Reference ID/Investigator# 30410

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Karlstadt : Site Reference ID/Investigator# 35482

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Karlstadt : Site Reference ID/Investigator# 49306

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Kassel : Site Reference ID/Investigator# 33964

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Kassel : Site Reference ID/Investigator# 33962

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kiel :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Kiel : Site Reference ID/Investigator# 29855

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Koeln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Koeln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Koeln : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Koenigs Wusterhausen : Site Reference ID/Investigator# 34000

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kolkwitz : Site Reference ID/Investigator# 35239

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Koln : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Köln :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Köln :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Konigs Wusterhausen : Site Reference ID/Investigator# 34002

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Konigs Wusterhausen : Site Reference ID/Investigator# 30412

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Kressbronn : Site Reference ID/Investigator# 34008

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Kressbronn : Site Reference ID/Investigator# 34006

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kressbronn : Site Reference ID/Investigator# 49257

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Kronach : Site Reference ID/Investigator# 34084

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Kronach : Site Reference ID/Investigator# 34009

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kyritz : Site Reference ID/Investigator# 34086

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Kyritz : Site Reference ID/Investigator# 49311

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Lahr : Site Reference ID/Investigator# 34005

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Lahr : Site Reference ID/Investigator# 34003

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Landau : Site Reference ID/Investigator# 35245

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Landau : Site Reference ID/Investigator# 30240

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leipzig :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Leipzig : Site Reference ID/Investigator# 34100

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Leipzig : Site Reference ID/Investigator# 34106

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Leipzig : Site Reference ID/Investigator# 34109

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Leipzig : Site Reference ID/Investigator# 34112

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Leipzig : Site Ref # / Investigator 65628

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Leipzig : Site Reference ID/Investigator# 34098

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Leipzig : Site Reference ID/Investigator# 34107

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Leipzig : Site Reference ID/Investigator# 53937

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Leipzig : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Leipzig : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Leipzig : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Leipzig : Site Reference ID/Investigator# 49298

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leipzig : Site Reference ID/Investigator# 30282

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leipzig : Site Reference ID/Investigator# 30456

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leipzig : Site Reference ID/Investigator# 30356

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leipzig : Site Reference ID/Investigator# 30455

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leipzig : Site Reference ID/Investigator# 49250

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leipzig : Site Reference ID/Investigator# 49310

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Leverkusen : Site Reference ID/Investigator# 34119

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Lichtenstein : Site Reference ID/Investigator# 34121

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Lichtenstein : Site Reference ID/Investigator# 30332

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Lingen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Lippstadt : Site Reference ID/Investigator# 35254

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Lippstadt : Site Reference ID/Investigator# 35252

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Lohne : Site Reference ID/Investigator# 53882

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Lubeck : Site Reference ID/Investigator# 34136

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ludwigsburg : Site Reference ID/Investigator# 53886

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ludwigsfelde :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Ludwigsfelde : Site Reference ID/Investigator# 35260

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ludwigsfelde : Site Reference ID/Investigator# 35257

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ludwigsfelde : Site Reference ID/Investigator# 30320

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ludwigshafen : Site Reference ID/Investigator# 35262

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ludwigshafen : Site Ref # / Investigator 51042

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ludwigslust : Site Reference ID/Investigator# 53906

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ludwigslust : Site Ref # / Investigator 53392

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Luebeck : Site Reference ID/Investigator# 34133

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Luebeck : Site Reference ID/Investigator# 49281

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Luedenscheid : Site Reference ID/Investigator# 53943

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Lueneburg : Site Reference ID/Investigator# 34139

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Lueneburg : Site Reference ID/Investigator# 33407

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Lueneburg : Site Reference ID/Investigator# 53888

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Lueneburg : Site Reference ID/Investigator# 30728

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Madgeburg : Site Reference ID/Investigator# 53913

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Madgeburg : Site Reference ID/Investigator# 34148

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Magdeburg : Site Reference ID/Investigator# 34147

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Magdeburg : Site Reference ID/Investigator# 34150

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Magdeburg : Site Reference ID/Investigator# 53981

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Magdeburg : Site Reference ID/Investigator# 30813

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Magdeburg : Site Reference ID/Investigator# 29852

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Mainz : Site Reference ID/Investigator# 35276

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Mainz : Site Reference ID/Investigator# 34154

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Mainz : Site Ref # / Investigator 65631

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Mainz : Site Reference ID/Investigator# 53928

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Mainz : Site Reference ID/Investigator# 49297

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Mannheim : Site Reference ID/Investigator# 34184

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Marktredwitz : Site Reference ID/Investigator# 34192

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Marktredwitz : Site Reference ID/Investigator# 22001

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Marl : Site Reference ID/Investigator# 34196

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Marl : Site Reference ID/Investigator# 34194

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Marl : Site Reference ID/Investigator# 29831

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Meissen : Site Reference ID/Investigator# 34200

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Menz : Site Reference ID/Investigator# 35285

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Menz : Site Reference ID/Investigator# 35283

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Menz : Site Reference ID/Investigator# 30266

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Merxheim : Site Reference ID/Investigator# 53896

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Minden : Site Reference ID/Investigator# 35287

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Minden : Site Reference ID/Investigator# 33418

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Minden : Site Reference ID/Investigator# 49277

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Mittelherwigsdorf : Site Reference ID/Investigator# 34208

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Mittelherwigsdorf : Site Reference ID/Investigator# 34206

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Mittelherwigsdorf : Site Reference ID/Investigator# 30238

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Moenchengladbach : Site Reference ID/Investigator# 34211

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Moenchengladbach : Site Reference ID/Investigator# 34214

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Moenchengladbach : Site Reference ID/Investigator# 34216

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Moenchengladbach : Site Reference ID/Investigator# 53915

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Moenchengladbach : Site Ref # / Investigator 51109

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Moenkeberg : Site Reference ID/Investigator# 34219

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Monchengladbach : Site Reference ID/Investigator# 34213

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Monchengladbach : Site Reference ID/Investigator# 34218

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Monkeberg : Site Reference ID/Investigator# 34221

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Monkeberg : Site Reference ID/Investigator# 49248

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Muelheim : Site Reference ID/Investigator# 35292

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Muelheim : Site Reference ID/Investigator# 49299

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Muenchen : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Muenchen : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Muenchen : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Muenchen : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Muenster : Site Reference ID/Investigator# 34048

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Muenster : Site Reference ID/Investigator# 34044

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Muenster : Site Reference ID/Investigator# 34046

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Muenster : Site Reference ID/Investigator# 53970

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Muenster : Site Reference ID/Investigator# 30710

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Muenster : Site Reference ID/Investigator# 49262

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Muhlhausen : Site Reference ID/Investigator# 34224

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Mullheim : Site Reference ID/Investigator# 34229

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Mullheim : Site Reference ID/Investigator# 49251

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Munchen : Site Reference ID/Investigator# 34232

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Munchen : Site Reference ID/Investigator# 34043

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Munchen : Krankenhaus Munchen Bogenhausen

Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

München :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

München :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

München : Study site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

München : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Munich : Site Reference ID/Investigator# 35295

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 34040

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 34235

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 35298

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 34041

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 53912

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 53956

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 53962

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 53924

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 53904

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 35296

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 34035

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Reference ID/Investigator# 34037

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Munich : Site Ref # / Investigator 53607

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Munich : Site Ref # / Investigator 53396

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Munich : Site Ref # / Investigator 53397

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Munich : Site Ref # / Investigator 53401

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Münster :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Naumburg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Naumburg : Site Reference ID/Investigator# 35306

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Naunhof :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Naunhof : Site Reference ID/Investigator# 34052

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Naunhof : Site Reference ID/Investigator# 34050

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Naunhof : Site Reference ID/Investigator# 49249

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Neubrandenburg : Site Reference ID/Investigator# 34061

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Neubrandenburg : Site Reference ID/Investigator# 34059

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Neubrandenburg : Site Reference ID/Investigator# 29812

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Neuburg : Site Reference ID/Investigator# 34062

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Neuburg : Site Reference ID/Investigator# 30719

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Neuburg 86633 : Site Reference ID/Investigator# 34064

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Neumunster : Site Reference ID/Investigator# 34071

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Neunkirchen : Site Reference ID/Investigator# 34980

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Neunkirchen : Site Reference ID/Investigator# 49254

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Neuss :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Neuss : Site Reference ID/Investigator# 35313

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Neuss : Site Reference ID/Investigator# 35311

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Neuss : Site Ref # / Investigator 53389

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Neustadt : Site Reference ID/Investigator# 34076

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Neustadt : Site Reference ID/Investigator# 34072

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Neustadt : Site Reference ID/Investigator# 30731

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Neuwied : Site Ref # / Investigator 65630

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Niederbrombach : Site Reference ID/Investigator# 35321

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Niefern : Site Reference ID/Investigator# 30439

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Niefern-Oeschelbronn : Site Reference ID/Investigator# 34078

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Niefern-Oschelbronn : Site Reference ID/Investigator# 34080

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Nienburg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Nienburg : Site Reference ID/Investigator# 34158

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Nienburg : Site Reference ID/Investigator# 34081

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Nienburg : Site Reference ID/Investigator# 34082

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Nienburg : Site Reference ID/Investigator# 30460

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Nienburg : Site Reference ID/Investigator# 30459

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Nuernberg : Site Reference ID/Investigator# 53923

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Nuremburg : Site Ref # / Investigator 51067

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Nurnberg : Site Reference ID/Investigator# 30704

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Nürnberg : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Oberammergau : Site Ref # / Investigator 51056

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Oberguenzburg : Site Reference ID/Investigator# 34168

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Oelsnitz : Site Reference ID/Investigator# 34173

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Offenburg : Site Reference ID/Investigator# 34176

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Offenburg : Site Reference ID/Investigator# 34174

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Offenburg : Site Reference ID/Investigator# 49243

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Oldenburg : Site Reference ID/Investigator# 33492

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Oldenburg : Site Reference ID/Investigator# 33490

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Oldenburg : Site Reference ID/Investigator# 30268

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Olsberg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Olsberg : Site Reference ID/Investigator# 53950

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Osnabrück :

An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)

Osnabrueck : Site Reference ID/Investigator# 54803

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Osnabrueck : Site Reference ID/Investigator# 33499

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Osnabrueck : Site Ref # / Investigator 51046

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Paderborn : Site Reference ID/Investigator# 35335

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Paderborn : Site Reference ID/Investigator# 35333

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Paderborn : Site Ref # / Investigator 51102

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Papenburg : Site Reference ID/Investigator# 33503

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Parchim : Site Reference ID/Investigator# 33508

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Parchim : Site Reference ID/Investigator# 33506

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Parchim : Site Reference ID/Investigator# 30402

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Parsberg : Site Reference ID/Investigator# 33509

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Passau : Site Reference ID/Investigator# 35340

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Passau : Site Reference ID/Investigator# 35338

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Passau : Site Reference ID/Investigator# 30718

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Petershagen : Site Reference ID/Investigator# 33511

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Pfullendorf : Site Reference ID/Investigator# 33517

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Pinneberg : Site Reference ID/Investigator# 33519

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Pirna : Site Reference ID/Investigator# 33520

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Pirna : Site Reference ID/Investigator# 30700

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Planegg : Site Reference ID/Investigator# 33523

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Planegg : Site Reference ID/Investigator# 33521

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Planegg : Site Reference ID/Investigator# 30206

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Plauen : Site Reference ID/Investigator# 33528

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Plauen : Site Reference ID/Investigator# 33526

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Plauen : Site Reference ID/Investigator# 30816

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Plochingen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Potsdam :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Potsdam : Site Reference ID/Investigator# 33466

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Potsdam : Site Reference ID/Investigator# 33470

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Potsdam : Site Reference ID/Investigator# 33468

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Potsdam : Site Reference ID/Investigator# 33464

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Potsdam : Site Reference ID/Investigator# 30441

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Potsdam : Site Reference ID/Investigator# 30790

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Prum : Site Reference ID/Investigator# 33476

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Prum : Site Reference ID/Investigator# 30352

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Puettlingen : Site Reference ID/Investigator# 33479

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Pulheim : Site Reference ID/Investigator# 53940

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Radebeul : Site Reference ID/Investigator# 33484

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Radebeul : Site Reference ID/Investigator# 35347

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Radebeul : Site Reference ID/Investigator# 33482

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Radebeul : Site Reference ID/Investigator# 30408

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Raststatt : Site Reference ID/Investigator# 53964

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ratingen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Ratingen : Site Reference ID/Investigator# 35136

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ratingen : Site Reference ID/Investigator# 35134

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ratingen : Site Reference ID/Investigator# 54812

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ratingen : Site Ref # / Investigator 33485

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ratingen : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Ratingen : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Ratingen : Site Reference ID/Investigator# 49309

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ratingen : Site Ref # / Investigator 64848

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ratzeburg : Site Reference ID/Investigator# 33488

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ratzeburg : Site Reference ID/Investigator# 30416

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Regensburg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Regensburg : Site Reference ID/Investigator# 33883

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 33890

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 33886

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 33881

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 33891

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 33884

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 33888

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 53930

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Regensburg : Site Reference ID/Investigator# 30736

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Reichenbach : Site Reference ID/Investigator# 51885

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Reichenbach : Site Reference ID/Investigator# 53986

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Reichenbach : Site Ref # / Investigator 64827

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Reichenbach : Site Ref # / Investigator 64824

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Reken : Site Reference ID/Investigator# 33897

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Reken : Site Reference ID/Investigator# 53957

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Reken : Site Reference ID/Investigator# 30738

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Remscheid : Site Reference ID/Investigator# 53920

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Rendsburg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Rendsburg : Site Reference ID/Investigator# 33902

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Rendsburg : Site Reference ID/Investigator# 33900

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Rendsburg : Site Reference ID/Investigator# 30316

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Reutlingen : Site Reference ID/Investigator# 33903

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Rheine :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Rheine : Site Reference ID/Investigator# 33907

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Rheine : Site Reference ID/Investigator# 30720

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Rheine : Site Ref # / Investigator 53605

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Rheinfelden : Site Reference ID/Investigator# 53982

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Rickenbach : Site Reference ID/Investigator# 35355

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Rickenbach : Site Reference ID/Investigator# 53908

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Riesa : Site Reference ID/Investigator# 33911

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Riesa : Site Reference ID/Investigator# 33393

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Riesa : Site Reference ID/Investigator# 30322

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Rinteln : Site Reference ID/Investigator# 33914

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Rinteln : Site Reference ID/Investigator# 33912

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Roehrnbach : Site Reference ID/Investigator# 33916

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Rostock :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Rostock :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Rostock : Site Reference ID/Investigator# 33927

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Rostock : Site Reference ID/Investigator# 33923

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Rostock : Site Reference ID/Investigator# 33921

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Rostock : Site Reference ID/Investigator# 30358

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Rostock : Site Reference ID/Investigator# 30447

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Rothenburg : Site Reference ID/Investigator# 33931

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Rothenburg : Site Reference ID/Investigator# 33929

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ruedersdorf : Site Reference ID/Investigator# 35362

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ruedersdorf : Site Reference ID/Investigator# 49276

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Saarbrücken :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Saarbruecken : Site Reference ID/Investigator# 34016

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Saarbruecken : Site Reference ID/Investigator# 34014

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Saarbruecken : Site Reference ID/Investigator# 30819

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Salzwedel : Site Reference ID/Investigator# 34023

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Salzwedel : Site Reference ID/Investigator# 34021

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Salzwedel : Site Reference ID/Investigator# 30709

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Sande : Site Reference ID/Investigator# 34027

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schlangenbad : Site Reference ID/Investigator# 53916

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Schneeberg : Site Reference ID/Investigator# 33534

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schneeberg : Site Reference ID/Investigator# 34030

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Schramberg : Site Reference ID/Investigator# 33539

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schramberg : Site Reference ID/Investigator# 30314

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Schutterwald : Site Reference ID/Investigator# 33542

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schwandorf : Site Reference ID/Investigator# 35371

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schwerin : Site Reference ID/Investigator# 33549

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schwerin : Site Reference ID/Investigator# 35376

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schwerin : Site Reference ID/Investigator# 33550

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Schwerin : Site Reference ID/Investigator# 35374

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Schwerin : Site Reference ID/Investigator# 30244

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Schwerin : Site Reference ID/Investigator# 30276

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Schwerin : Site Ref # / Investigator 51070

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Schwerte : Site Reference ID/Investigator# 33555

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Schwerte : Site Reference ID/Investigator# 33553

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Seesen : Site Reference ID/Investigator# 33559

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Seesen : Site Reference ID/Investigator# 33557

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Seesen : Site Reference ID/Investigator# 30236

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Senden : Site Reference ID/Investigator# 33563

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Sendenhorst :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Siegen : Site Reference ID/Investigator# 53944

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Siegen : Site Reference ID/Investigator# 53945

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Singen : Site Reference ID/Investigator# 35380

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Singen : Site Reference ID/Investigator# 49305

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Sinsheim : Site Reference ID/Investigator# 33567

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Sinsheim : Site Reference ID/Investigator# 33565

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Sinsheim : Site Reference ID/Investigator# 30388

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Solingen : Site Reference ID/Investigator# 53927

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Soltau : Site Reference ID/Investigator# 33572

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Soltau : Site Reference ID/Investigator# 33570

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Soltau : Site Reference ID/Investigator# 30418

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Spremberg : Site Reference ID/Investigator# 33577

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

St. Martin : Site Reference ID/Investigator# 35383

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Stadtbergen : Site Reference ID/Investigator# 33583

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Stadthagen : Site Reference ID/Investigator# 33588

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Stadthagen : Site Reference ID/Investigator# 33586

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Stadthagen : Site Reference ID/Investigator# 49267

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Steinhagen : Site Reference ID/Investigator# 33592

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Steinhagennnd : Site Reference ID/Investigator# 53936

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Stuttgart :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Stuttgart : Site Reference ID/Investigator# 33604

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Stuttgart : Site Reference ID/Investigator# 33598

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Stuttgart : Site Reference ID/Investigator# 33607

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Stuttgart : Site Reference ID/Investigator# 33611

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Stuttgart : Site Reference ID/Investigator# 33596

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Stuttgart : Site Reference ID/Investigator# 33602

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Stuttgart : Site Reference ID/Investigator# 33609

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Stuttgart : Site Reference ID/Investigator# 49291

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Stuttgart : Site Reference ID/Investigator# 49265

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Suhl : Site Reference ID/Investigator# 35389

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Suhl : Site Reference ID/Investigator# 35387

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Suhl : Site Reference ID/Investigator# 49255

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Tarp : Site Reference ID/Investigator# 54808

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Tegernau : Site Reference ID/Investigator# 35391

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Thum-Jahnsbach : Site Reference ID/Investigator# 35433

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Tischenreuth : Site Reference ID/Investigator# 53951

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Torgelow : Site Reference ID/Investigator# 33625

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Torgelow : Site Reference ID/Investigator# 33623

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Torgelow : Site Reference ID/Investigator# 30384

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Traunstein :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Treuenbrietzen : Site Ref # / Investigator 33628

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Treuenbrietzen : Site Reference ID/Investigator# 30712

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Treuenbrietzen : Site Ref # / Investigator 51101

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Tübingen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Tuebingen : Site Reference ID/Investigator# 53907

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Tuebingen : Site Reference ID/Investigator# 49269

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Twistringen : Site Reference ID/Investigator# 53893

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ueberlingen : Site Reference ID/Investigator# 33637

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ueberlingen : Site Reference ID/Investigator# 33635

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ueberlingen : Site Reference ID/Investigator# 30024

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Uffenheim : Site Reference ID/Investigator# 35395

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Uhlstaedt-Kirchhasellow : Site Reference ID/Investigator# 53898

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ulm : Germany Site Reference ID/Investigator# 33724

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ulm : Site Reference ID/Investigator# 33721

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ulm : Site Ref # / Investigator 65626

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ulm : Site Reference ID/Investigator# 33722

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Ulm : Site Reference ID/Investigator# 30370

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ulm : Site Ref # / Investigator 51062

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Verden : Site Reference ID/Investigator# 33732

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Viersen : Site Reference ID/Investigator# 33734

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Viersen : Site Reference ID/Investigator# 53965

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Villingen : Site Reference ID/Investigator# 33737

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Villingen-schwenningen :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Villingen-schwenningen :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Villingen-Schwenningen : Site Reference ID/Investigator# 33735

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Villingen-Schwenningen : Site Reference ID/Investigator# 30274

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Voehringen : Site Reference ID/Investigator# 35397

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Vogelsang-Gommern : Site Reference ID/Investigator# 53914

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Vreden : Site Reference ID/Investigator# 53952

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Waldbronn : Site Reference ID/Investigator# 54809

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Waltrop : Site Reference ID/Investigator# 33742

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Waltrop : Site Reference ID/Investigator# 33740

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Waltrop : Site Reference ID/Investigator# 30732

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Weener : Site Reference ID/Investigator# 33747

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Weener : Site Reference ID/Investigator# 30378

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Weener 26826 : Site Reference ID/Investigator# 33749

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

WeiBenfels : Site Reference ID/Investigator# 33751

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Weiden i.d. Oberpfalz : Site Reference ID/Investigator# 53891

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Weissenfels : Site Reference ID/Investigator# 53921

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Weissenfels : Site Reference ID/Investigator# 29825

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Welzow : Site Reference ID/Investigator# 33852

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Welzow : Site Reference ID/Investigator# 33753

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Welzow : Site Reference ID/Investigator# 30133

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wiefelstede : Site Reference ID/Investigator# 35404

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 33761

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 35408

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 35413

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 33765

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 35406

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 33762

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 53941

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wiesbaden : Site Reference ID/Investigator# 30278

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wiesbaden : Site Reference ID/Investigator# 49300

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wiesbaden : Site Reference ID/Investigator# 49246

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wiesbaden : Site Reference ID/Investigator# 30420

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wiesbaden : Site Ref # / Investigator 64825

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wilhelmshaven : Site Reference ID/Investigator# 33772

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wilhelmshaven : Site Reference ID/Investigator# 33770

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wilhelmshaven : Site Reference ID/Investigator# 30466

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Winsen : Site Reference ID/Investigator# 53954

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Winsen : Site Reference ID/Investigator# 49296

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Winsen (Luhe) : Site Reference ID/Investigator# 53977

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wittlich : Site Reference ID/Investigator# 33780

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wittlich : Site Reference ID/Investigator# 33778

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wittlich : Site Reference ID/Investigator# 30175

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wolfsburg : Site Reference ID/Investigator# 33783

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wuerzburg : Site Reference ID/Investigator# 33718

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wuerzburg : Site Reference ID/Investigator# 33716

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wuerzburg : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Wuerzburg : Site Reference ID/Investigator# 49304

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Wuppertal :

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Wuppertal : Site Reference ID/Investigator# 35420

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Wuppertal : Site Reference ID/Investigator# 53917

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wuppertal : Site Reference ID/Investigator# 35418

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Wuppertal : Site Reference ID/Investigator# 49264

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Würzburg :

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Würzburg : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Zerbst : Site Reference ID/Investigator# 33864

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Zerbst : Site Reference ID/Investigator# 33862

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Zerbst : 59

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Zerbst : Site Reference ID/Investigator# 30468

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Zeven : Site Reference ID/Investigator# 33867

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Zeven : Site Reference ID/Investigator# 33865

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Zeven : Site Reference ID/Investigator# 30173

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Zwickau : Site Reference ID/Investigator# 33876

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Zwickau : Site Reference ID/Investigator# 33873

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Zwickau : Site Reference ID/Investigator# 33870

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Zwickau : Site Reference ID/Investigator# 30302

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Zwiesel : Site Reference ID/Investigator# 33880

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Zwiesel : Site Reference ID/Investigator# 33878

Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Zwiesel : Site Reference ID/Investigator# 30810

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Greece

Agrinio : Site Ref # / Investigator 53645

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Agrinio : Site Ref # / Investigator 40873

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Argos : Site Ref # / Investigator 40746

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Athens :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Athens :

An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

View More »

Athens : Investigational Site Number 300001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Athens : Site Ref # / Investigator 40864

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Athens : Site Ref # / Investigator 40714

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Heraklion : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Heraklion : Investigational Site Number 300002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Kallithea : Site Ref # / Investigator 40755

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Katerini : Site Ref # / Investigator 40921

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Komotini : Site Ref # / Investigator 41024

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Lamia : Site Ref # / Investigator 40718

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Livadeia : Site Ref # / Investigator 40733

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Nea Smyrni : Site Ref # / Investigator 40740

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Pefki : Site Ref # / Investigator 40853

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Thessaloniki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Thessaloniki :

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

Thessaloniki :

An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

Thessaloniki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Thessaloniki : Investigational Site Number 300003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Thessaloniki : Site Ref # / Investigator 40716

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Thessaloniki : Site Ref # / Investigator 40713

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Thessaloniki : Site Ref # / Investigator 41030

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Triandria : Site Ref # / Investigator 41023

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Hong Kong

Hong Kong :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Hungary

Baja : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Baja : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Balassagyarmat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Balassagyarmat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Balatonfured : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

View More »

Balatonfured : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Balatonfured : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Balatonfured : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Bekescsaba : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Bekescsaba : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Budapest :

A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Budapest : MSD Magyarorszag Kft.

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM2 EXT 1)

Budapest :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Budapest : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Budapest : 18

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Budapest : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Budapest : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Budapest : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Budapest : Investigational Site Number 348006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Budapest : Investigational Site Number 348014 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Budapest : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Budapest : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Budapest : Location n°8 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Budapest : Location n°6 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Debrecen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Debrecen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Debrecen :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Debrecen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Debrecen : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Debrecen : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Debrecen : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Debrecen : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Debrecen : Investigational Site Number 348003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Debrecen : Investigational Site Number 348010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Debrecen : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Debrecen : Location n°7 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Eger :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Eger : Investigational Site Number 348011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Eger : Location n°10 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Esztergom : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Esztergom :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Esztergom : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Gy?r : Investigational Site Number 348013 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Gyor : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Gyula :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Gyula : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Kecskemet :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Kiskunhalas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Kiskunhalas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Kiskunhalas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kistarcsa :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Kistarcsa : Location n°9 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Mako : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Miskolc :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Nyiregyhaza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Nyiregyhaza :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Nyiregyhaza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Satoraljaujhely : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Satoraljaujhely : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Satoraljaujhely : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Sátoraljaújhely : Investigational Site Number 348005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Sopron : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Szeged :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Szekesfehervar :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Szentes : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Szikszo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Szikszo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Szikszo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Szolnok :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Szombathely :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Szombathely : Investigational Site Number 348015 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Veszprem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Veszprem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Veszprem :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Veszprem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Veszprem : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Veszprém : Investigational Site Number 348004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Zalaegerszeg : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Zalaegerszeg-pozva : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

India

Ahmedabad : Rathi Orthopaedic & Research Center

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Ahmedabad : Shalby Hospitals

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Ahmedabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Ahmedabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Ahmedabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

View More »

Ahmedabad : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Bangalore : M S Ramaiah Medical College and Hospital

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bangalore : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Chandigarh :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biologic DMARD and/or Anti-TNF Therapy

Chennai : Chennai Meenakshi Multispeciality Hospital Limited

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Chennai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Chennai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Chennai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Coimbatore : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hyderabaad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Hyderabaad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Hyderabaad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hyderabad : Advance Rheumatology Clinic

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Hyderabad : Mahavir Hospital and Research Center

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Hyderabad : Sri Deepti Rheumatology Center

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Hyderabad : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hyderabad : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Jaipur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Jaipur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Jaipur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Jaipur : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Lucknow : Chhatrapati Shahuji Maharaj Medical University

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Lucknow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Lucknow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lucknow : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Madurai : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mangalore : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mumbai :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biologic DMARD and/or Anti-TNF Therapy

Mysore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Mysore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Mysore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Nagpur : Sushrut Hospital Research Centre and PG Institute of Orthopaedics

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Nagpur : Vidarbha Arthritis & Superspeciality Clinic

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Nagpur : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Nellore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Nellore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Nellore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

New Delhi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

New Delhi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

New Delhi :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biologic DMARD and/or Anti-TNF Therapy

New Delhi : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Pune : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Secunderabad : Krishna Institute of Medical Sciences

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Secunderabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Secunderabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Secunderabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Secunderabad : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Surat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Surat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Surat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Vadodara : Centre for Knee & Hip Surgery

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Vadodara : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Indonesia

Bandung :

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

East Java :

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

Malang :

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

Yogyakarta :

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

Ireland

Cork : Site Ref # / Investigator 49402

A Study on the Prevalence of the Anti-MCV Anti-body in an Irish Rheumatoid Arthritis (RA) Population and the Impact of Biomarker Status on the Management of Irish Patients With Early RA

Dublin :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Dublin : 54

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Dublin 24 : Site Ref # / Investigator 22307

A Study on the Prevalence of the Anti-MCV Anti-body in an Irish Rheumatoid Arthritis (RA) Population and the Impact of Biomarker Status on the Management of Irish Patients With Early RA

Limerick : 32

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Israel

Ashkelon : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Ashkelon : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ashkelon : Barzilai Medical Center

Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

Haifa : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Haifa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

View More »

Kfar Saba : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Petah-tikva : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Ramat Gan : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Rishon Lezion :

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Tel Aviv :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Tel Aviv : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Tel-hashomer : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Italy

Ancona :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Ancona : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Arenzano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Arenzano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bergamo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

View More »

Bergamo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Cagliari : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Catania : 08

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Chieti : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Ferrara :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Ferrara : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Ferrara : 10

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Florence : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Gazzi :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Jesi : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Jesi : 01

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Legnano : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Messina : Location n°15 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Milano :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Milano : Study site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Milano : 05

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Milano : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Milano : Location n°16 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Modena :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Novara :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Palermo : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Parma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Pavia :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Pisa :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Pisa : Location n°17 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Prato :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Reggio Emilia : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Roma :

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Roma :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

San Cesario Di Lecce :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

San Giovanni Rotondo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

San Giovanni Rotondo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Saronno :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Siena : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Siena : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Siena : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Torino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Trieste :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Udine : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Valeggio Sul Minicio : 02

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Varese :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Verona :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Viterbo :

An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Japan

Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Aichi : Site Ref # / Investigator 65002

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Aichi : Site Ref # / Investigator 65014

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

View More »

Aichi : Site Ref # / Investigator 62159

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Aichi : Site Ref # / Investigator 64925

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Aichi : Site Ref # / Investigator 64971

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Aichi : Site Ref # / Investigator 65362

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Aichi : Site Ref # / Investigator 65382

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Aichi : Site Ref # / Investigator 67197

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Arakawa-ku : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Asahikawa : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Bunkyo-ku : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Bunkyo-Ku : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Chiba : 102

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Chiba : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Chiba : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Chiba : Site Ref # / Investigator 62118

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Chiba : Site Ref # / Investigator 64977

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Chiba : Site Ref # / Investigator 62454

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Chiba : Site Ref # / Investigator 65394

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Chiba : Site Ref # / Investigator 62441

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Chiba : Site Ref # / Investigator 62155

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Chiba-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Chiba-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Chiyoda-ku : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Chiyoda-ku : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Chubu Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Chugoku Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Ehime : Site Ref # / Investigator 57248

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Fuchu : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Fukui : Site Ref # / Investigator 62147

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukui : Site Ref # / Investigator 57603

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukui-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Fukuoka : 114

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Fukuoka : 115

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Fukuoka : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Fukuoka : Site Ref # / Investigator 62110

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Fukuoka : Site Ref # / Investigator 47402

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Fukuoka : Site Ref # / Investigator 62156

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 62230

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 62232

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 64981

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 64962

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 65337

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 62143

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 65390

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka : Site Ref # / Investigator 62228

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukuoka-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Fukuoka-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Fukuoka-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Fukuoka-shi : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Fukushima : Site Ref # / Investigator 65307

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukushima : Site Ref # / Investigator 62157

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukushima : Site Ref # / Investigator 62234

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukushima : Site Ref # / Investigator 67176

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Fukusima : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Gifu : Site Ref # / Investigator 62096

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Gifu : Site Ref # / Investigator 67227

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Gifu : Site Ref # / Investigator 67267

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Goshogawara : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Gunma : Site Ref # / Investigator 62088

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Gunma : Site Ref # / Investigator 65384

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Gunma : Site Ref # / Investigator 65392

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Gunma : Site Ref # / Investigator 64980

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Gunma : Site Ref # / Investigator 62146

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hamamatsu : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Hamamatsu : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Hamamatsu-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Hamamatsu-shi : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Hannan : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Higashi-Hiroshima-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Hiroshima : 113

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Hiroshima : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Hiroshima : Site Ref # / Investigator 62137

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hiroshima-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Hiroshima-city : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Hitachi-shi : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hokkaido : Site Ref # / Investigator 65326

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido : Site Ref # / Investigator 67192

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido : Site Ref # / Investigator 64964

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido : Site Ref # / Investigator 65335

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido : Site Ref # / Investigator 62237

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido : Site Ref # / Investigator 62238

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido : Site Ref # / Investigator 62436

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido : Site Ref # / Investigator 62438

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hokkaido Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Hyogo : Site Ref # / Investigator 65044

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Hyogo : Site Ref # / Investigator 62440

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hyogo : Site Ref # / Investigator 64908

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hyogo : Site Ref # / Investigator 62239

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Hyogo : Site Ref # / Investigator 65349

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Ibaragi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Ibaragi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Ibaragi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Ibaraki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Ibaraki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Ibaraki : Site Ref # / Investigator 62116

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Ibaraki : Site Ref # / Investigator 62135

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Ibaraki : Site Ref # / Investigator 62125

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Ibaraki : Site Ref # / Investigator 64960

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Ibaraki : Site Ref # / Investigator 62241

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Ibaraki : Site Ref # / Investigator 62130

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Iizuka : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Iizuka-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Ishikawa : Site Ref # / Investigator 62244

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Ishikawa : Site Ref # / Investigator 65368

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Itabashi : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Itabashi-ku : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kagoshima : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Kagoshima : Site Ref # / Investigator 62100

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Kagoshima : Site Ref # / Investigator 62247

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kagoshima : Site Ref # / Investigator 62150

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kagoshima : Site Ref # / Investigator 62456

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kakogawa : 120

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Kakogawa : Konan Kakogawa Hospital

Quality of Sleep in Patients With Rheumatoid Arthritis

Kamakura : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kanagawa : Site Ref # / Investigator 62099

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Kanagawa : Site Ref # / Investigator 62105

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Kanagawa : Site Ref # / Investigator 62119

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Kanagawa : Site Ref # / Investigator 62429

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 62253

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 62260

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 64906

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 65320

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 65397

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 62140

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 62258

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanagawa : Site Ref # / Investigator 67188

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kanto Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Kasama : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Kato-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Kawachinagano : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kawachinagano : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kawagoe-shi : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kawasaki-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kinki Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Kitakyushu : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kitakyushu-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Kitakyushu-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Kitakyusyu : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kitamoto : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kofu : 109

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Koto-ku : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Koushi : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kumamoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Kumamoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Kumamoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kumamoto : 118

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Kumamoto : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kumamoto : Site Ref # / Investigator 62108

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Kumamoto : Site Ref # / Investigator 65387

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kumamoto : Site Ref # / Investigator 65019

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kumamoto : Site Ref # / Investigator 62443

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kumamoto-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kurashiki : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kurashiki-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kurume : 116

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Kurume : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kyoto : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Kyoto : Site Ref # / Investigator 62445

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kyoto : Site Ref # / Investigator 67178

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kyoto : Site Ref # / Investigator 65395

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kyoto : Site Ref # / Investigator 64955

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Kyushu Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Matsuyama : 121

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Meguro-ku : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Mie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Mie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Mie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Mie : Site Ref # / Investigator 65356

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Mie : Site Ref # / Investigator 65354

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Miyagi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Miyagi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Miyagi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Miyagi : Site Ref # / Investigator 67240

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Miyagi : Site Ref # / Investigator 62430

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Miyagi : Site Ref # / Investigator 62432

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Miyagi : Site Ref # / Investigator 62151

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Miyazaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Miyazaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Miyazaki : Site Ref # / Investigator 62085

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Miyazaki : Site Ref # / Investigator 62152

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Miyazaki : Site Ref # / Investigator 62262

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Miyazaki : Site Ref # / Investigator 65316

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Miyazaki-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Musashimurayama-shi : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Nagano : Site Ref # / Investigator 62098

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Nagano : Site Ref # / Investigator 62120

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Nagano : Site Ref # / Investigator 62128

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Nagano : Site Ref # / Investigator 65343

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Nagano-Shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Nagano-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Nagaoka : 107

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Nagasaki : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Nagasaki : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Nagasaki : Site Ref # / Investigator 62113

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Nagasaki : Site Ref # / Investigator 62264

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Nagasaki : Site Ref # / Investigator 62160

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Nagasaki : Site Ref # / Investigator 62131

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Nagasaki-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Nagoya : 110

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Nagoya : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Nagoya : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Nagoya-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Nagoya-shi, 23 : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Nara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Nara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Nara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Nara : Site Ref # / Investigator 62086

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Nara : Site Ref # / Investigator 64904

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Nara : Site Ref # / Investigator 65005

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Narashino : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Narita : 103

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Niigata : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Niigata : Site Ref # / Investigator 65052

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Niigata : Site Ref # / Investigator 57245

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Niigata : Site Ref # / Investigator 64954

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Ohita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Ohita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Ohita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Ohmura : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Oita : 119

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Oita : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Oita : Site Ref # / Investigator 65010

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Oita : Site Ref # / Investigator 62265

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Oita : Site Ref # / Investigator 62266

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Okayama : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Okayama : 112

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Okayama : Site Ref # / Investigator 62083

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Okayama : Site Ref # / Investigator 67269

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Okayama : Site Ref # / Investigator 62104

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Okayama : Site Ref # / Investigator 62459

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Okayama : Site Ref # / Investigator 62462

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Okayama : Site Ref # / Investigator 62267

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Okayama : Site Ref # / Investigator 62268

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Okayama : Site Ref # / Investigator 65308

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Okinawa : Site Ref # / Investigator 62109

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Omura-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Omura-shi : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Osaka : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Osaka : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Osaka : Site Ref # / Investigator 57247

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Osaka : Site Ref # / Investigator 65309

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 64978

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 64922

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 67179

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 65358

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 62269

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 62270

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 62271

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 62452

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 65344

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 65331

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 65334

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 65352

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 65367

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 65369

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 67198

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka : Site Ref # / Investigator 62136

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Osaka-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Saga : Site Ref # / Investigator 65324

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Sagamihara : 106

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Sagamihara : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Sagamihara : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Sagamihara-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Saitama : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Saitama : Site Ref # / Investigator 65051

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Saitama : Site Ref # / Investigator 65046

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Saitama : Site Ref # / Investigator 67243

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Saitama : Site Ref # / Investigator 62124

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Saitama : Site Ref # / Investigator 62272

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Saitama : Site Ref # / Investigator 62126

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Saitama : Site Ref # / Investigator 62139

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Saitama : Site Ref # / Investigator 65339

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Saitama : Site Ref # / Investigator 64939

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Saitama : Site Ref # / Investigator 65304

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Sapporo : 100

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Sapporo : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Sapporo : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Sapporo : Site Ref # / Investigator 62082

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Sapporo-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Sapporo-Shi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Sapporo-Shi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Sapporo-Shi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Sasebo : 117

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Sasebo : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Sasebo-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Sasebo-shi : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Sasebo-shi : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Sasebo-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Sawara-ku : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Sendai : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Sendai : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Sendai : 392001001

Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis

Shiga : Site Ref # / Investigator 62428

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Shikoku Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Shimane : Site Ref # / Investigator 62427

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Shinjuku : Research Site

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Shinjuku-ku : Research Site

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Shinjuku-ku : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Shinjuku-Ku : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Shinjuku-ku, Tokyo : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Shinjyuku-ku : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Shizuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Shizuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Shizuoka : Site Ref # / Investigator 57246

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Shizuoka : Site Ref # / Investigator 62102

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Shizuoka : Site Ref # / Investigator 62274

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Shizuoka : Site Ref # / Investigator 65346

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Shizuoka : Site Ref # / Investigator 65338

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Shizuoka-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Taishaku : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Takasaki : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Tochigi : Site Ref # / Investigator 62101

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Tochigi : Site Ref # / Investigator 65329

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tochigi : Site Ref # / Investigator 62425

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tohoku Region :

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Tokorozawa-city : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Tokushima : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tokyo : Site Ref # / Investigator 65048

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Tokyo : Site Ref # / Investigator 65053

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Tokyo : Site Ref # / Investigator 62103

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Tokyo : Site Ref # / Investigator 62107

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Tokyo : Site Ref # / Investigator 67244

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Tokyo : Site Ref # / Investigator 64903

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 64990

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 65372

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 62446

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 62455

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 62275

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 62276

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 62277

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 65348

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 65327

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tokyo : Site Ref # / Investigator 50022

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tomakomai : 101

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Tomigusuku-Shi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Tonami : 108

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Toshima-Ku : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Tottori : Site Ref # / Investigator 62448

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Toyama : Site Ref # / Investigator 65045

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Toyama : Site Ref # / Investigator 57249

Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))

Toyama : Site Ref # / Investigator 62279

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Toyama : Site Ref # / Investigator 62431

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Tsu : 111

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Tsukuba : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Ureshino : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Yamagata : Site Ref # / Investigator 64928

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Yamaguchi : Site Ref # / Investigator 62281

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Yamaguchi : Site Ref # / Investigator 65365

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Yamaguchi : Site Ref # / Investigator 62134

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Yamaguchi : Site Ref # / Investigator 62162

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Yamanashi : Site Ref # / Investigator 62282

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Yokohama : 105

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Yotsukaido : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Yotukaido : 104

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Yotukaidou : Pfizer Investigational Site

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Korea, Republic of

Busan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Busan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Busan :

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)

Busan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Busan : Investigational Site Number 410006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

View More »

Daegu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Daegu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Daegu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Daegu : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Daegu : Investigational Site Number 410004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Daegu : Investigational Site Number 410013 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Daejeon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Daejeon :

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)

Daejeon : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Daejeon : 200

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Daejeon : Investigational Site Number 410005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Daejeon : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Gangnam-Gu : 205

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Gwang Ju :

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

Gwangju : Investigational Site Number 410010 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Gyeonggi-do :

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)

Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Incheon : Investigational Site Number 410009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Incheon : Investigational Site Number 410001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Jeonju : Investigational Site Number 410011 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Jung-gu : 201

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Seongdong-gu : 202

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Seongnam-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Seongnam-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Seoul :

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)

Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Seoul : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Seoul : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Seoul : 203

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Seoul : 204

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Seoul : Investigational Site Number 410012 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Seoul : Investigational Site Number 410002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Seoul : Investigational Site Number 410003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Seoul : Investigational Site Number 410007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Seoul : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Seoul : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Seoul : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Suwon : Investigational Site Number 410008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Latvia

Liepaja : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Riga : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Valmiera : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lebanon

Beirut :

An Observational Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Lithuania

Alytus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Alytus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kaunas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Kaunas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kaunas : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

View More »

Kaunas : Investigational Site Number 440001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Klaipeda : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Klaipedos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Klaipedos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Klaipedos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Panevezys : Location n°30 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Siauliai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Siauliai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Siauliai : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Vilnius : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Vilnius : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Vilnius : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Vilnius : Investigational Site Number 440002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Vilnius : Location n°28 Updated

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Malaysia

Batu Caves : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Batu Caves : Site Ref # / Investigator 36098

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Batu Caves : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Ipoh : Site Ref # / Investigator 57914

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Ipoh : Investigational Site Number 458001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

View More »

Johor Bahru : Site Ref # / Investigator 57923

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Klang : Site Ref # / Investigator 67602

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Kota Bahru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Kota Bahru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kota Kinabalu : Site Ref # / Investigator 57925

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Kuala Lumpur : Site Ref # / Investigator 57916

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Kuantan : Site Ref # / Investigator 57928

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Kuantan Pahang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Kuantan Pahang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Kuching : Site Ref # / Investigator 57924

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Kuching : Investigational Site Number 458002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Melaka : Site Ref # / Investigator 57927

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Patrajaya : Site Ref # / Investigator 57915

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Penang : Site Ref # / Investigator 57913

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Putrajaya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Putrajaya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Putrajaya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Putrajaya : Investigational Site Number 458003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Serdang : Site Ref # / Investigator 57926

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Seremban : Site Ref # / Investigator 57922

A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia

Mexico

Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Barrio San Mateo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Barrio San Mateo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

View More »

Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Chihuahua : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Chihuahua : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Chihuahua : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Chihuahua : Site Ref # / Investigator 55265

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Culiacan :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Culiacan : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

D.f. : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

DF : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Durango : Investigational Site Number 484008 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Guadalajara :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Guadalajara : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Guadalajara : Investigational Site Number 484002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Guadalajara : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Guadalajara : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Leon :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Merida : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Merida : Investigational Site Number 484004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Merida : Investigational Site Number 484009 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Metepec : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Metepec : Investigational Site Number 484007 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Mexicali : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Mexicali : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Mexicali : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Mexico : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Mexico City : Investigational Site Number 484003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Mexico City : Site Ref # / Investigator 55268

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Mexico City : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Mexico Ctiy :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Mexico, D.F. : Investigational Site Number 484001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Monterrey : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Monterrey : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Monterrey : Investigational Site Number 484005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Monterrey : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Morelia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Morelia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Morelia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Morelia : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Obregon :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Obrergon : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Obrergon : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Queretaro : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Saltillo :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Saltillo : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Saltillo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

San Luis Potosi : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

San Luis Potosi : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

San Luis Potosi : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

San Luis Potosi : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Tijuana : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tijuana : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tijuana : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tijuana : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Tlalpan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Torreon :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Monaco

Monaco :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Netherlands

Alkmaar :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Amersfoort :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Amsterdam : Academic Medical Center, University of Amsterdam

Long Term Extension Study For SPM-005 Participants

Amsterdam : 009

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Amsterdam : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

View More »

Amsterdam : Academic Medical Center, University of Amsterdam

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Beek en Donk : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

Boxtel : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

Den Helder :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Dordrecht : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

Gouda :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Groningen :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Haarlem :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Hoofddorp :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Hoogwoud : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

Leeuwarden :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Leids : Nycomed Investigational Site

A Trial to Evaluate the Safety and Tolerability of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis

Nijmegen :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Nijmegen : 012

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Nijverdal : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

's-Hertogenbosch : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

Sneek :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Spijkenisse : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

Stationsweg 163 : PRA International (PRA)

Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects

Utrecht :

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Utrecht : 010

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Vlodrop : Research Site

Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns

New Zealand

Auckland :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Christchurch : Investigational Site Number 554004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

View More »

Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Rotorua : Investigational Site Number 554002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Tauranga : Investigational Site Number 554003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Timaru : Investigational Site Number 554001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Norway

Ålesund : Helse Sunnmøre HF, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Bergen : Helse Bergen HF, Haukeland University Hospital, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Drammen : Vestre Viken HF, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Haugesund : Haugesund Sanitetsforening Revmatismesykehus

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Kristiansand : Revmatologene bendvold/Dovland

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

View More »

Kristiansand : Sørlandet Sykehus HF, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Kristiansand : Investigational Site Number 578004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lillehammer : Lillehammer Hospital for Rheumatic Diseases

Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment

Moss : Sykehuset Østfold HF, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Oslo : Diakonhjemmet Sykehus AS, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Sandvika : Martina Hansens Hospital AS

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Tønsberg : Investigational Site Number 578006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Tromsø : Universitetssykehuset Nord-Norge HF, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Trondheim : St Olavs Hospital HF, Dept. of Rheumatology

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Peru

Arequipa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lima : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Lima : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lima : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Borja : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Philippines

Makati City : Merck Sharp & Dohme (I.A.) Corporation

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM2 EXT 1)

Poland

Bialystok : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Bialystok : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Bialystok : Investigational Site Number 616002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bialystok : Investigational Site Number 616003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Bydgoszcz : Oddział Kliniczny Reumatologii i Ukladowych Chorob Tkanki Lacznej

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

View More »

Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Bytom : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Bytom : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Chelm Slaski : Centrum Medyczne MEDENS S.C. Grupowa Praktyka Lekarska

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Chelm Slaski : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Czestochowa : Specjalistyczna Praktyka Lekarska Joanna Badowska

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Dzialdowo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Dzialdowo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Gdynia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Gdynia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Grodzisk Mazowiecki : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Grodzisk Mazowiecki : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Katowice : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Katowice : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Krakow : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Krakow : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Krakow : Investigational Site Number 616001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lublin : NZOZ Reumed

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Lublin :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Lublin : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Lublin : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Lublin : Investigational Site Number 616005 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Nadarzyn : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Plock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Plock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Poznan :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Poznan : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Poznan : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Poznan : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Poznan : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Torun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Torun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Torun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Torun : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Torun : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Torun : Investigational Site Number 616006 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients

Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Patients With Rheumatoid Arthritis

Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Open Label Study for Patients With Rheumatoid Arthritis

Warszawa : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Warszawa : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Warszawa : Investigational Site Number 616004 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Warszawa : 019

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Warszawa : Local Institution

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Warszawa : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Wloszczowa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

Wroc#Aw : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Wroclaw : Wojewodzki Zespol Specjalistycznej Opieki Zdrowotnej

A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Wroclaw : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Wroclaw : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Zyrardow : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Zyrardow : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Portugal

Almada :

A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arhtritis and an Inadequate Response to Non-biological DMARDs

Aveiro : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Aveiro : Investigational Site Number 620003 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lisboa :

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Reponders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

Lisboa : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

View More »

Lisboa : Investigational Site Number 620001 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lisboa : Investigational Site Number 620002 Updated

Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Lisbon : Site Ref # / Investigator 55204

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Porto : Hospital de Santo Antonio

An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement

Porto : Research Site

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Puerto Rico

Caguas : Site Ref # / Investigator 55487

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

San Juan : Site Reference ID/Investigator# 38691

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

San Juan : Pfizer Investigational Site Updated

Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

Vega Baja : Site Reference ID/Investigator# 60851

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Vega Baja : Site Ref # / Investigator 54942

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)